| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Gene Therapies | Rare Diseases | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Gene Therapies | Rare Diseases | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Gene Therapies | Rare Diseases |
Recent Updates
Recently added Catalysts
Inovio Pharmaceuticals, Inc.$1.18
-0.01 (-0.84%)
C 49Pipeline Score Fair Value Pharma · Clinical
Market Cap
111.07 M
EPS
-1.71
P/E Ratio
-
Value Trade
2.06 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
14.07 M
Operating CF
-21.59 M
Total Assets
49.78 M
Total Liabilities
43.71 M
Equity
6.07 M
D/E Ratio
12,345
0 %
Week
18.42 %
1 Month
-19.64 %
3 Month
-21.74 %
6 Month
-98.42 %
5 Year
-99.81 %
All Time
Cash Data
Cash Position
37.68 M
Monthly Burn
7.20 M
Runway
3.5 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
1.59 M
52 Week Range
1.03 - 2.98
% held by Insiders
0.47 %
% held by Institutions
38.12 %
Enterprise Value
82.08 M
Total Shares
82.24 M
Short %
18.57 %
Float Shares
81.01 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Inovio Pharmaceuticals, Inc.
1466Total events
10Upcoming
404Tier-1 (high impact)
2010 – 2026Coverage
Upcoming catalysts 10
Event history 1456
Q3 2026
◆First Patient DosedINO-5412Trial
Dosing expected to begin in the second half of 2026 for INO-5412 plus cadonilimab combination in INSIGhT trial
glioblastoma (GBM)source ↗
Jun 11, 2026
◆Poster PresentationPresentation
World Orphan Drug Congress Poster: Rare Disease Protein Replacement Therapeutics
Rare Diseasesource ↗
Jun 4, 2026
Jun 2026
◆FDA ApprovalINO-3107ApprovedFDA Decision
Potential FDA approval in mid-2026
Recurrent Respiratory Papillomatosis (RRP)source ↗
Jun 2026
◆PDUFA DateINO-3107ApprovedRegulatory Filing
PDUFA date for INO-3107 if priority review granted
recurrent respiratory papillomatosis (RRP)source ↗
May 30, 2026
◆Poster PresentationINO-3107ApprovedPresentation
B cell responses in Recurrent Respiratory Papillomatosis patients treated with DNA immunotherapy INO-3107
Recurrent Respiratory Papillomatosissource ↗
May 21, 2026
▲Topline ReadoutVGX-3100Clinical Data
Positive topline results from pivotal Phase 3 trial of VGX-3100 in cervical dysplasia
HPV-16/18-associated cervical dysplasia (HSIL)source ↗
May 21, 2026
▲Primary Endpoint MetVGX-3100Clinical Data
Primary endpoint met in Phase 3 trial of VGX-3100
HPV-16/18-associated cervical dysplasia (HSIL)source ↗
May 13, 2026
May 13, 2026
●Mid Cycle CommunicationINO-3107ApprovedRegulatory Filing
Mid-cycle review meeting completed with FDA
Recurrent Respiratory Papillomatosis (RRP)source ↗
May 13, 2026
●Oral PresentationINO-3107ApprovedPresentation
Data from Phase 1/2 trial of INO-3107 presented at COSM
Recurrent Respiratory Papillomatosis (RRP)source ↗
May 12, 2026
◆Poster PresentationPresentation
Bleeding phenotype correction in hemophilia A mice following in vivo Factor VIII gene transfer by electroporation in skeletal muscle cells
hemophilia Asource ↗
Drug Pipeline Intelligence
C49
Pipeline Score $199M
Pipeline ValueFair Value
Valuation Signal26
Drugs Scored1.8x
rNPV / MCap Top 74%
Micro Cap (rank 238 of 911)
Percentile RankInovio Pharmaceuticals, Inc. carries a moderate pipeline score (49/100), with $7.0B risk-adjusted pipeline value, led by PENNVAX-B in HIV-1 Infection (Phase 1), across $175B in total addressable markets, but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PENNVAX-B Monoclonal antibody | HIV-1 Infection | Phase 1 | NCT01082692 | 22% | $1.2B | COMPLETED | 12 | - | - | Aug 1, 2012 | - | Nov 9, 2012 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
DNA-encoded monoclonal antibodies (DMAbs) | COVID-19 | Phase 1 | 2025-10-21 | 39/39 maintained biologically relevant levels of DMAbs through week 72 follow up; DMAbs successfully bound to the SARS-CoV-2 Spike protein and neutralized the SARS-CoV-2 pseudovirus target in all tested participants; no participant developed anti-drug antibodies (ADA) across ~1,000 blood samples; serum concentrations reaching a peak of 1.61 μg/mL Read More | Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine Read More | |
DNA-encoded monoclonal antibodies (DMAbs) | COVID-19 | Phase 1 | 2025-10-21 | 39/39 maintained biologically relevant levels of DMAbs through week 72 follow up; DMAbs successfully bound to the SARS-CoV-2 Spike protein and neutralized the SARS-CoV-2 pseudovirus target in all tested participants; no participant developed anti-drug antibodies (ADA) across ~1,000 blood samples; serum concentrations reaching a peak of 1.61 μg/mL Read More | Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine Read More | |
DNA-encoded monoclonal antibodies (DMAbs) | COVID-19 | Phase 1 | 2025-10-21 | 39/39 maintained biologically relevant levels of DMAbs through week 72 follow up; DMAbs successfully bound to the SARS-CoV-2 Spike protein and neutralized the SARS-CoV-2 pseudovirus target in all tested participants; no participant developed anti-drug antibodies (ADA) across ~1,000 blood samples; serum concentrations reaching a peak of 1.61 μg/mL Read More | Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
INOINOVIO to Participate in Upcoming Scientific and Investor Conferences
INOVIO Pharmaceuticals, focused on DNA medicines for HPV-related diseases and cancer, announced its participation in upcoming scientific and investor conferences. Notably, it will have a fireside chat at the Jefferies Global Healthcare Conference and a poster presentation at the World Orphan Drug Congress. The management team will also hold one-on-one meetings with investors, likely to strengthen their financial and collaborative engagements.
Read more →INOPositive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO’s Partner in China
INOVIO's partner ApolloBio announced positive topline results from a Phase 3 trial of VGX-3100, an investigational DNA immunotherapy for cervical dysplasia. The trial met its primary efficacy endpoint and showed a favorable safety profile. ApolloBio plans to use these results for a future regulatory submission in China, potentially offering a non-surgical treatment option for patients.
Read more →INOINOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights
INOVIO reported its financial results for Q1 2026, highlighting advancements in its lead product INO-3107 for recurrent respiratory papillomatosis (RRP). The FDA is reviewing the BLA for INO-3107, with a target PDUFA date set for October 30, 2026. INOVIO is also collaborating with Akeso Inc. to evaluate INO-5412 for glioblastoma treatment. The company remains focused on commercialization strategies and financial discipline.
Read more →INO▲ +6.6%on this newsshared move
INOVIO to Participate in Upcoming Scientific Conferences
INOVIO (NASDAQ:INO) has announced its participation in two prominent scientific conferences, the American Society of Gene and Cell Therapy Annual Meeting in Boston and the American Society of Clinical Oncology Annual Meeting in Chicago. At these events, the company will present research related to gene treatments for hemophilia A and DNA immunotherapy for Recurrent Respiratory Papillomatosis. Following the presentations, abstracts will be made available on INOVIO's website to share further details of the research.
Read more →INOINOVIO to Report First Quarter Financial Results on May 13, 2026
INOVIO Pharmaceuticals will release its first quarter 2026 financial results on May 13, 2026, after market close. A live conference call and webcast will follow at 4:30 p.m. ET, allowing analysts to engage in a Q&A session. The webcast will be archived for 90 days for later access.
Read more →INO▼ -35.1%on this news
INOVIO Announces Proposed Public Offering
INOVIO Pharmaceuticals announced its intention to conduct a public offering of common stock and warrants. The offering will be managed by Piper Sandler, with a potential 30-day option for additional shares. The company filed a shelf registration statement with the SEC, but the offering's completion depends on market conditions.
Read more →INO▼ -35.1%on this newsshared move
INOVIO Announces Pricing of $17.5 Million Public Offering
INOVIO Pharmaceuticals has announced a public offering of 12.5 million shares, aiming to raise approximately $17.5 million. The offering includes Series A and Series B warrants, with a public offering price of $1.40 per share. The transaction is expected to close on April 6, 2026, pending customary conditions. Piper Sandler is managing the offering.
Read more →INOINOVIO to Participate in Upcoming Scientific Conference
INOVIO (NASDAQ:INO) has announced its participation in the World Federation of Hemophilia World Congress in Kuala Lumpur. The company will present on its DNA-Encoded Protein (DPROT) technology and its non-viral vector DNA medicine platform for hemophilia A. Abstracts will be available on INOVIO's website after the presentations.
Read more →INOINOVIO DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INO
Rosen Law Firm is reminding Inovio Pharmaceuticals investors of the impending April 7, 2026, deadline for a lead plaintiff in a securities class action. The lawsuit claims that during the Class Period from October 10, 2023, to December 26, 2025, Inovio made false statements regarding its CELLECTRA device and the prospects of submitting a Biologics License Application for INO-3107. Investors may be entitled to compensation, and those interested in participating are encouraged to seek counsel to ensure representation. Significant risks have been highlighted, with investors experiencing damages linked to misleading communications from the company.
Read more →INOINOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
INOVIO has reported its financial results for Q4 and full year 2025, highlighting the FDA's acceptance of its BLA for INO-3107 under review. The company is focused on advancing this treatment for recurrent respiratory papillomatosis while also preparing for commercialization. Positive clinical trial results support the efficacy of INO-3107, although the FDA has raised concerns about the adequacy of the submitted data for accelerated approval.
Read more →INOInovio Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – INO
Inovio Pharmaceuticals, Inc. is facing a securities class action lawsuit from shareholders who purchased stock during the specified class period. The lawsuit alleges that the company made materially false or misleading statements related to its CELLECTRA device and the regulatory status of its lead product candidate, INO-3107. It claims that manufacturing deficiencies and insufficient information impacted the prospects for FDA submission and approval. Shareholders are encouraged to register for participation in the legal proceedings by the April 7, 2026 deadline.
Read more →INOINOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
INOVIO Pharmaceuticals will announce its fourth quarter and full year 2025 financial results on March 12, 2026. The announcement will be followed by a live conference call and webcast at 4:30 p.m. ET, where the company will discuss the results and provide a business update. The event will include a Q&A session with analysts.
Read more →INOAkeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) - March 4, 2026
Akeso and INOVIO have entered a clinical collaboration to evaluate the combination of cadonilimab and INO-5412 for glioblastoma treatment. This partnership will be part of the INSIGhT Phase II trial, aiming to discover new therapies for this aggressive cancer. Dosing is expected to begin in the latter half of 2026, leveraging the strengths of both companies' innovative treatments.
Read more →INOINOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
INOVIO and Akeso have announced a clinical collaboration to evaluate the combination of INO-5412 and cadonilimab for treating glioblastoma (GBM). The trial will be part of the INSIGhT platform, aimed at rapidly identifying effective therapies for this aggressive cancer type. This partnership builds on promising Phase 2 results indicating that the combination may enhance survival rates. Dosing for the trial is set to begin in the latter half of 2026.
Read more →INOINOVIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inovio Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against Inovio Pharmaceuticals, alleging that the company made misleading statements regarding its INO-3107 Biologics License Application (BLA) process and manufacturing practices. The lawsuit claims these statements falsely overstated the prospects for the drug's regulatory approval. As a result, Inovio's stock price fell sharply after the FDA indicated that the BLA did not meet the criteria for accelerated approval. Investors have until April 7, 2026 to apply to lead the class action lawsuit.
Read more →INOInovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 7, 2026 to Discuss Your Rights – INO
Inovio Pharmaceuticals, Inc. is under scrutiny due to a class action securities lawsuit filed by Levi & Korsinsky on February 19, 2026. The lawsuit claims that the company misled investors regarding the manufacturing deficiencies of its CELLECTRA device and the regulatory status of its product candidate, INO-3107. Allegations include overstating the commercial prospects of INO-3107 and failing to provide adequate information for FDA approval. Investors affected by these claims have until April 7, 2026, to assert their rights in court.
Read more →INOINOVIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Inovio Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against Inovio Pharmaceuticals, alleging that the company made misleading statements regarding its manufacturing capabilities and the regulatory prospects of its product, INO-3107. The lawsuit claims that Inovio's public communications overestimated the product's eligibility for FDA approval, leading to significant losses for investors. Following the announcement that the FDA accepted Inovio's BLA for standard review rather than accelerated approval, Inovio's stock price saw a notable decline. Investors affected by potential losses are encouraged to seek legal guidance.
Read more →INO▼ -24.5%on this news
FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)
INOVIO's Biologics License Application for INO-3107 has been accepted by the FDA for review as a treatment for adults with recurrent respiratory papillomatosis (RRP). The FDA has set a PDUFA review goal date of October 30, 2026, but raised concerns about the adequacy of data for accelerated approval. INOVIO believes INO-3107 offers significant therapeutic benefits and plans to discuss next steps with the FDA.
Read more →INOINOVIO Reports Inducement Grant Under Inducement Plan
INOVIO Pharmaceuticals announced an equity grant of stock options to a newly hired employee under its 2022 Inducement Plan. The Compensation Committee approved the award of 24,000 shares, set to vest over three years contingent on the employee's continued employment. The stock options have an exercise price matching INOVIO's common stock closing price on the grant date. This move signifies the company's efforts to expand its workforce and incentivize new talent.
Read more →INOINOVIO to Participate in December Investor Conferences
INOVIO Pharmaceuticals, a biotech firm specializing in DNA medicines, announced its participation in two upcoming investor conferences in December. The events include the Piper Sandler 37th Annual Healthcare Conference and the Oppenheimer Movers in Rare Disease Summit. Management will also hold one-on-one meetings with investors to discuss potential catalysts.
Read more →INO▼ -7%on this news
INOVIO Announces Pricing of $25 Million Public Offering
INOVIO Pharmaceuticals has announced a public offering of 13,158,000 shares at $1.90 each, aiming to raise approximately $25 million. The offering is expected to close on November 12, 2025, pending customary conditions. Piper Sandler & Co. is managing the offering, which is part of a previously filed shelf registration with the SEC.
Read more →INO▼ -7%on this newsshared move
INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights
INOVIO Pharmaceuticals reported its Q3 2025 financial results, highlighting the completion of the rolling submission of its BLA for INO-3107, aimed at treating recurrent respiratory papillomatosis. The company anticipates a potential approval in mid-2026, with ongoing preparations for commercialization. Despite positive trial results, INOVIO faces significant financial losses and liabilities.
Read more →INO▲ +6.4%on this news
INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults
INOVIO has completed the rolling submission of its Biologics License Application (BLA) for INO-3107, a DNA immunotherapy aimed at treating recurrent respiratory papillomatosis (RRP) in adults. The submission is under the FDA's Accelerated Approval program, with a request for priority review. If approved, INO-3107 would be INOVIO's first commercial product and the first DNA medicine available in the U.S.
Read more →INO▲ +6.9%on this news
INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025
INOVIO Pharmaceuticals, Inc. announced it will release its third quarter 2025 financial results on November 10, 2025, after the market closes. The company will host a live conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide an update on its business activities. INOVIO focuses on developing DNA medicines for HPV-related diseases and other health conditions, showcasing its commitment to addressing significant health challenges.
Read more →INOINOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
INOVIO Pharmaceuticals will participate in the Stephens Biotechnology Virtual Fireside Chat Conference on November 4, 2025. The event will feature members of INOVIO's management team engaging in one-on-one meetings with investors. This initiative underscores INOVIO's focus on developing DNA medicines for HPV-related diseases and other conditions.
Read more →INO▼ -5.7%on this newsshared move
Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine
INOVIO announced positive results from a Phase 1 trial of DNA-encoded monoclonal antibodies (DMAbs) for COVID-19, published in Nature Medicine. The trial demonstrated that all participants maintained effective levels of DMAbs for 72 weeks and showed successful binding and neutralization of the virus. The study highlights DMAbs' potential as a long-lasting alternative to traditional monoclonal antibody therapies.
Read more →INOINOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults
INOVIO has announced that the FDA has agreed to its rolling submission timeline for the Biologics License Application (BLA) for INO-3107, intended for treating adults with Recurrent Respiratory Papillomatosis (RRP). The company anticipates submitting the application in the coming months, aiming for acceptance by the end of 2025. INO-3107 has demonstrated promising results in reducing the need for surgeries in patients, while being granted both Orphan Drug and Breakthrough Therapy designations. Despite these positive developments, the path to regulatory approval remains uncertain due to potential challenges in clinical trials.
Read more →INOINOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
INOVIO (NASDAQ:INO) announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, where a pre-recorded presentation will be available beginning September 5, 2025. Members of INOVIO's management team will conduct in-person meetings with investors during the conference. The company focuses on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, showcasing its innovative approach to healthcare.
Read more →INOINOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights On track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end Completed desi
INOVIO announced its second quarter 2025 financial results and highlighted advancements toward submitting a Biologics License Application (BLA) for INO-3107 in the latter half of 2025. With successful design verification testing of the CELLECTRA 5PSP device, the company aims for FDA acceptance of its submission by year-end. Clinical data published shows INO-3107 significantly reduced surgeries for patients with Recurrent Respiratory Papillomatosis (RRP). Despite improvements, INOVIO continues to face financial losses and may need additional funding to support ongoing operations.
Read more →INOData Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)
INO-3107 has shown promising results in reducing the need for surgeries in patients with Recurrent Respiratory Papillomatosis (RRP), with Overall Response Rates increasing from 72% at Year 1 to 86% at Year 2. The Complete Response rate also improved from 28% to 50% during the same period. Furthermore, the mean number of surgeries required by patients dropped remarkably to 0.9 in the second year. It is noted that the treatment was well tolerated among participants without any serious adverse events.
Read more →INOINOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025
INOVIO has announced the release date for its second quarter 2025 financial results, which will be available after market close on August 12, 2025. A live conference call and webcast will follow to discuss the results and offer a business update. The company specializes in DNA medicines targeting HPV-related diseases, cancers, and infectious diseases.
Read more →INOINOVIO to Present at Upcoming Scientific Conference
INOVIO (NASDAQ:INO) will present its advancements in DNA medicine at the Orphan Drug Summit in Boston. The company's presentation will focus on the transformative potential of its next generation DNA medicine technology specifically designed for rare diseases. This opportunity to showcase their work at a major conference reflects INOVIO's commitment to combating HPV-related diseases, cancer, and infectious diseases through innovative approaches. The conference is expected to foster collaboration among industry leaders and innovators in the rare disease field.
Read more →INOINOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respirato
INOVIO has announced its financial results for the first quarter of 2025, highlighting progress in its Biologics License Application for INO-3107 aimed at treating recurrent respiratory papillomatosis. The company is also reporting promising clinical results from both INO-3107 and its DNA-encoded monoclonal antibodies. Despite a substantial net loss, INOVIO expresses confidence in its product development plans and remains focused on securing FDA approval. The company’s cash reserves are projected to support operations into early 2026, barring any additional capital-raising efforts.
Read more →INOINOVIO to Present at Upcoming Scientific and Investor Conferences
INOVIO (NASDAQ: INO) announced its upcoming presentations at multiple scientific and investor conferences, including a fireside chat at the Citizens JMP Life Sciences Conference in New York. The company will share data regarding its lead candidate INO-3107 at significant events such as the ABEA program and the European Laryngological Society Annual Congress. These presentations will focus on the long-term effects of INO-3107 in treating recurrent respiratory papillomatosis linked to HPV. Abstracts from these presentations will be available on INOVIO's website after the events.
Read more →INOINOVIO to Report First Quarter 2025 Financial Results on May 13, 2025
INOVIO Pharmaceuticals has announced it will release its financial results for the first quarter of 2025 on May 13, 2025, after the market close. Following the release, the company will host a live conference call and webcast to discuss the results and provide business updates. The call is designed for analysts and will include a Q&A session. INOVIO focuses on developing DNA medicines for HPV-related diseases, cancers, and infectious diseases.
Read more →INO▲ +8.9%on this news· ran to +21% by day 3
INOVIO to Present at Upcoming Scientific Conferences
INOVIO (NASDAQ: INO) will present key data regarding its lead candidate, INO-3107, at various upcoming scientific conferences, including the National HPV Conference and the World Vaccine Congress. Notably, INO-3107 achieved a 72% overall response rate in treating recurrent respiratory papillomatosis associated with HPV. Additionally, the company will showcase discussions on their novel DNA-encoded monoclonal antibody technology at the World Vaccine Congress. The information and available abstracts will be disclosed on INOVIO's website following the presentations.
Read more →INOINOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurre
INOVIO has reported its financial results for Q4 and full year 2024, indicating significant advancements in its operational pipeline. The company is on track to submit a Biologics License Application (BLA) for INO-3107, targeting recurrent respiratory papillomatosis (RRP), aiming for a rolling submission start in mid-2025. Promising interim results from ongoing trials of DNA-encoded monoclonal antibodies (DMAb) for COVID-19 have shown well-tolerated outcomes with long-lasting antibody production. INOVIO is also progressing plans for a Phase 3 trial for INO-3112 in oropharyngeal squamous cell carcinoma.
Read more →INO▼ -5.9%on this newsshared move
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
INOVIO has announced promising interim results from a Phase 1 proof-of-concept trial evaluating DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19. The study showed that all 24 participants maintained stable levels of DMAbs for 72 weeks, with no instances of anti-drug antibodies detected. Most reported side effects were mild and temporary. These findings suggest that this new technology could potentially transform treatments for infectious diseases and other conditions by enabling long-term expression of therapeutic proteins.
Read more →INO▲ +5.1%on this newsshared move
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025
INOVIO has announced that it will report its fourth quarter and year-end financial results for 2024 on March 18, 2025. Following the release, the company will host a live conference call at 4:30 p.m. ET to discuss the financial outcomes and offer a general business update. The event will be available online, and participants will have the opportunity to engage in a Q&A session. The webcast will be archived for 90 days for later access.
Read more →INO▲ +12.1%on this news
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications
INOVIO has published positive data from its Phase 1/2 clinical trial of INO-3107, demonstrating significant clinical benefits for patients with recurrent respiratory papillomatosis (RRP). The trial indicated that 81.3% of participants required fewer surgeries post-treatment, correlating with the induced immune response against HPV-6 and HPV-11. INO-3107 is expected to be submitted for FDA approval in mid-2025 and could become the first DNA therapy approved for any indication in the U.S. The treatment was well tolerated, although some patients reported mild adverse events.
Read more →INOImmune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
INOVIO Pharmaceuticals is set to present an abstract on INO-3107 at the upcoming AACR Immuno-Oncology Conference. The poster will detail the loss of detectable HPV-6 in patients with Recurrent Respiratory Papillomatosis following treatment. This presentation highlights the immunological activity of INO-3107, and the abstract will be accessible on INOVIO's website after the event. The conference occurs from February 23-26, 2025, and focuses on innovations in immunotherapy.
Read more →INO▼ -7.3%on this news
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
INOVIO (NASDAQ:INO) announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, scheduled for February 12, 2025. The company will be represented by Dr. Jacqueline Shea, President and CEO, alongside Chief Medical Officer Dr. Michael Sumner. The event provides an opportunity for INOVIO's management to engage with registered investors through one-on-one meetings. A webcast of the presentation will be accessible on their Investor Relations Events page.
Read more →INO▼ -5.3%on this news
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
INOVIO Pharmaceuticals has outlined its anticipated milestones for 2025, highlighting the submission of a biologics license application for INO-3107, aimed at treating recurrent respiratory papillomatosis. The company reports key accomplishments from 2024, including promising clinical data showing that many patients achieved complete responses without the need for surgery. As it aims to enter commercial stages, INOVIO has also made progress in strengthening its financial position and preparing for upcoming trials.
Read more →INO▼ -38.3%on this news· ran to -53% by day 3
INOVIO Announces Pricing of $30 Million Public Offering
INOVIO Pharmaceuticals, Inc. has announced a public offering priced at $3.00 per share, looking to raise $30 million by offering 10 million shares along with warrants. The company plans to close the offering on December 16, 2024, subject to customary conditions. This step is part of INOVIO's strategy to secure funding for its DNA medicines aimed at combating HPV-related diseases and cancer, but market conditions pose a risk to the offering's execution. Investors may find potential in the warrants attached to the shares, enhancing the deal's attractiveness.
Read more →INONew Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial
New retrospective data from INOVIO shows that INO-3107 significantly improves treatment outcomes for Recurrent Respiratory Papillomatosis (RRP) patients. After 2 years, 50% of treated patients achieved a Complete Response, which increased to 54% by year 3. Most patients either maintained or improved their Overall Response Rate from the initial treatment. The findings highlight the potential of INO-3107 as a durable, non-surgical option for RRP, with further research and presentations planned for the future.
Read more →INOINOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights - New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of
INOVIO has announced its third quarter 2024 financial results, highlighting the progress of its lead candidate INO-3107. Recent immunology data show that INO-3107 can induce antigen-specific T-cell responses, which could benefit patients with recurrent respiratory papillomatosis (RRP). The company is on track to submit a biologics license application (BLA) by mid-2025, despite facing a net loss and decreasing cash reserves.
Read more →INOImmunology Data Shows INOVIO
INOVIO announced positive immunology data for INO-3107, indicating its ability to induce clonal T cell expansion in patients with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and HPV-11. The data, which will be presented at the 36th International Papillomavirus Conference, supports previous findings from a Phase 1/2 trial where most patients experienced a reduction in required surgical interventions. This new research highlights the potential for INO-3107 to effectively address the immune dysregulation associated with HPV. Clinical experts express optimism about these findings reflecting the efficacy of DNA medicines in treating HPV-related diseases.
Read more →INOINOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024
INOVIO has scheduled the release of its third quarter 2024 financial results for November 14, 2024, after the market closes. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial outcomes and provide a general business update. The event will feature a live Q&A session, enhancing interaction with analysts and stakeholders.
Read more →INOINOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP
INOVIO announced new positive data on its lead candidate INO-3107 for treating Recurrent Respiratory Papillomatosis (RRP) at recent scientific conferences. Immunology data indicated INO-3107's ability to induce T cell responses specific to HPV-6 and HPV-11, with an impressive 81% of clinical trial participants requiring fewer surgeries post-treatment. The candidate is well tolerated, with manageable side effects, and is on track for a Biologics License Application targeted for mid-2025 under the FDA's Accelerated Approval Pathway.
Read more →INOINOVIO Reports Inducement Grants Under Inducement Plan
INOVIO has announced equity grants to two newly hired employees under its 2022 Inducement Plan. The Compensation Committee has approved restricted stock units and stock options, set to vest over three years, aimed at incentivizing the new hires. Each grant is contingent upon the employees maintaining their positions at INOVIO throughout the vesting period. This move reflects INOVIO's commitment to ensuring a motivated and stable workforce as it develops innovative DNA medicines.
Read more →INOINOVIO Reports Second Quarter 2024 Financial Results and Recent Business Highlights
INOVIO recently reported its financial results for Q2 2024, highlighting progress on its lead candidate INO-3107 for recurrent respiratory papillomatosis. The company is on track to submit a Biologics License Application (BLA) by mid-2025, following a positive meeting with the FDA. However, a manufacturing issue was detected with a component of their device, which may impact the timeline. INOVIO is also advancing other programs, including INO-3112 for oropharyngeal squamous cell carcinoma, while managing a net cash burn that could influence their operational capabilities into 2025.
Read more →INOInovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107
INOVIO has received certification from the European Medicines Agency's Committee for Advanced Therapies for its lead candidate INO-3107, confirming compliance with quality and non-clinical data standards. This positions INO-3107 for potential European Marketing Authorization Application as a treatment for Recurrent Respiratory Papillomatosis (RRP). Clinical trial results indicate significant reductions in surgical interventions among patients treated with INO-3107, supported by favorable immune response metrics. Furthermore, INO-3107 has already garnered Orphan Drug and Breakthrough Therapy designations from the FDA, facilitating expedited development pathways.
Read more →INOINOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024
INOVIO Pharmaceuticals, Inc. has announced that it will release its second quarter 2024 financial results after the market close on August 8, 2024. Following the results announcement, the company will conduct a live conference call and webcast to discuss the financial results and provide a general business update. The event is expected to engage investors and analysts through a live Q&A session. INOVIO specializes in developing DNA medicines targeting HPV-related diseases, cancer, and other infectious diseases.
Read more →INO▲ +19%on this news
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government
INOVIO's lead DNA medicine candidate, INO-3107, has received the Innovation Passport designation from the U.K. government under the Innovative Licensing and Access Pathway (ILAP) to address Recurrent Respiratory Papillomatosis (RRP). This designation will facilitate a faster development and regulatory approval process, supporting INOVIO's goal to provide an innovative treatment option for patients suffering from this chronic condition. The drug demonstrated promising results in Phase 1/2 trials, indicating its potential effectiveness in reducing the need for surgical interventions among patients.
Read more →INOINOVIO Announces Appointment of Steven Egge as Chief Commercial Officer
INOVIO has appointed Steven Egge as Chief Commercial Officer, who brings over 25 years of biopharmaceutical experience. The company is preparing to launch its first DNA medicine product, INO-3107, as it plans to submit a Biologics License Application in the second half of 2024 under the FDA's Accelerated Approval Pathway. This strategic move may enhance INOVIO's commercial viability and position it as a leader in treating recurrent respiratory papillomatosis (RRP). Egge's past experiences and skills will support INOVIO's efforts in building commercial strategies and capabilities.
Read more →INO▲ +6.6%on this newsshared move
INOVIO Added to Russell 2000® Index Effective July 1, 2024
INOVIO (NASDAQ: INO) has been added to the Russell 2000 Index effective July 1, 2024, following the annual reconstitution. This inclusion is indicative of the company's growth and strategic focus, especially on its lead candidate INO-3107 for RRP. INOVIO aims to submit a Biologics License Application for INO-3107 in the latter half of 2024 and is preparing for a potential commercial launch in 2025, contingent on approval. The company continues to advance other product candidates, showing a commitment to innovation in the biopharma sector.
Read more →INOINOVIO to Participate in Virtual Fireside Chat Hosted by Stephens Inc.
INOVIO (NASDAQ: INO) has announced its participation in a virtual fireside chat hosted by Stephens Inc., featuring President and CEO Dr. Jacqueline Shea and Chief Medical Officer Dr. Michael Sumner. This event will take place on June 11, 2024, and is exclusively for institutional clients. INOVIO focuses on developing DNA medicines targeting HPV-related diseases, cancer, and infectious diseases, showcasing its ongoing commitment to advancing healthcare solutions.
Read more →INO▲ +6.7%on this news· ran to +20% by day 3
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical
INOVIO has announced its financial results for Q1 2024, highlighting progress toward a BLA submission for INO-3107, which targets Recurrent Respiratory Papillomatosis (RRP). The company aims to file under the accelerated approval pathway in the second half of 2024, potentially becoming the first approved DNA medicine in the U.S. INOVIO is also advancing its trials for INO-3112, a candidate for treating HPV-related head and neck cancer. Despite these advancements, INOVIO anticipates a significant cash burn in the upcoming quarter and faces uncertainties in clinical development timelines.
Read more →INO▲ +8.8%on this newsshared move
INOVIO to Participate in Upcoming Investor Conferences in May
INOVIO (NASDAQ: INO) announced its participation in three investor conferences in May 2024, where CEO Dr. Jacqueline Shea will present in a fireside chat format. The conferences are The Citizens JMP Life Sciences Conference, RBC Capital Markets 2024 Global Healthcare Conference, and H.C. Wainwright 2nd Annual BioConnect Investor Conference. INOVIO aims to enhance investor relations and provide updates on its developments in DNA medicines targeting HPV-related diseases, cancer, and infectious diseases.
Read more →INO▲ +8.8%on this newsshared move
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024
INOVIO (NASDAQ:INO) announced that it will report its first quarter 2024 financial results on May 13, 2024, after the market closes. The company specializes in DNA medicines aimed at treating various diseases, including HPV-related illnesses and cancer. Following the financial report, INOVIO will host a live conference call and webcast to discuss the results and provide updates on its business. This event underscores INOVIO's ongoing commitment to transparency and stakeholder engagement.
Read more →INOINOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
INOVIO Pharmaceuticals announced the pricing of an underwritten offering of approximately $36 million, selling over 2.5 million shares of its common stock and over 2 million pre-funded warrants. The offering price is set at $7.693 per share and $7.692 per warrant, before underwriting discounts. This public offering is expected to close around April 18, 2024, subject to standard conditions. The company aims to use the proceeds to further its development of DNA medicines targeting HPV-related diseases and other infections.
Read more →INOINOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
INOVIO (NASDAQ:INO) announced that its CEO, Dr. Jacqueline Shea, will participate in the Citizens JMP Novel Therapeutics Forum at Penn Medicine on April 2, 2024. The event will highlight innovative technologies for treating and preventing diseases. Dr. Shea's presence underscores the company's leadership in DNA medicine development and its focus on addressing HPV-related diseases, cancer, and infectious diseases.
Read more →INOINOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
INOVIO reported its fourth-quarter and full-year 2023 financial results, highlighting significant advancements in its lead program INO-3107 for Recurrent Respiratory Papillomatosis (RRP). The company received Breakthrough Therapy Designation from the FDA and plans to submit a Biological License Application (BLA) under the accelerated approval program by late 2024. INOVIO also announced positive results from clinical trials involving INO-3112 and INO-4201, while reducing operating expenses significantly during the year. Financial metrics show a decrease in cash reserves, raising concerns about future funding and operational capability.
Read more →INOINOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
INOVIO has announced the release date for its fourth quarter and year-end 2023 financial results, which will occur after the market closes on March 6, 2024. Following the announcement, the company will conduct a live conference call and webcast at 4:30 p.m. ET. This event aims to discuss the financial outcomes and offer a general business update while allowing for a Q&A session with analysts. INOVIO specializes in DNA medicines aimed at addressing HPV-related diseases, cancer, and infectious diseases.
Read more →INOINOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
INOVIO (NASDAQ:INO) announced that Dr. Jacqueline Shea, President and CEO, will be presenting at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024. The conference will feature a fireside chat format and includes opportunities for one-on-one meetings with registered investors. A webcast of the presentation will be made available for 90 days following the event on the INOVIO Investor Relations Events page.
Read more →INO▼ -16.1%on this news
INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split
INOVIO (NASDAQ: INO) announced a 1-for-12 reverse stock split of its shares effective January 24, 2024. This move is aimed at regaining compliance with Nasdaq's minimum bid price requirement. Post-split, the number of outstanding shares will decrease significantly, from approximately 280.1 million to about 23.3 million. The reverse stock split will not change the par value per share and will affect all stockholders uniformly.
Read more →INOINOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader
INOVIO has announced its participation in a virtual fireside chat to discuss potential treatments for Recurrent Respiratory Papillomatosis (RRP). Scheduled for January 24, 2024, the event will feature key leaders including INOVIO's President and CEO, Dr. Jacqueline Shea, and Dr. Michael Sumner, the Chief Medical Officer. The discussion highlights the urgent need for new therapeutic modalities for RRP, featuring insights from Dr. Simon Best of Johns Hopkins University. The event underscores INOVIO's commitment to addressing HPV-associated diseases.
Read more →INO▼ -7.7%on this news· ran to +31% by day 3
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program
INOVIO announced plans to submit a Biological License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) in the second half of 2024. The company will request Rolling Submission and Priority Review from the FDA to expedite the review process. INO-3107 has already garnered Orphan Drug and Breakthrough Therapy designations from the FDA, indicating strong early regulatory support. A confirmatory trial will also be initiated prior to the BLA submission, with hopes for a product launch in 2025.
Read more →INOINOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights Achieved significant progress with lead product candidate, INO-3107 Received Breakthrough Therapy designation from U.S. Food and Drug Adminis
INOVIO has reported its financial results for Q3 2023, highlighting substantial progress with its lead product candidate INO-3107, which recently received Breakthrough Therapy designation from the FDA. The company anticipates submitting a Biologics License Application (BLA) without the need for a Phase 3 trial and aims to expedite its commercialization strategy for INO-3107. In clinical trials, INO-3107 demonstrated a notable reduction in surgical interventions for patients with Recurrent Respiratory Papillomatosis (RRP), positioning it as a significant improvement over current treatments. INOVIO is focusing its resources and strategy on advancing INO-3107 and enhancing its operational efficiencies.
Read more →INOINOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023
INOVIO (NASDAQ: INO) has announced that it will release its financial results for the third quarter of 2023 on November 9, 2023, after market close. Along with the financial report, the company will host a live conference call and webcast at 4:30 p.m. ET to discuss its results and provide an update on its business. INOVIO specializes in developing DNA medicines aimed at treating HPV-related diseases, cancer, and infectious diseases.
Read more →INO▲ +41%on this news
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program Previously planned Phase 3 trial no longer required to support Biological L
INOVIO announced that the FDA has indicated the data from its completed Phase 1/2 trial of INO-3107 could be used for a BLA submission under the accelerated approval program. Importantly, the FDA noted that the previously planned Phase 3 trial is no longer necessary for this submission. The company must still initiate a confirmatory trial before submission and has not finalized the trial design. If approved, INO-3107 would be the first DNA medicine to receive regulatory approval in the U.S., with promising results already seen in reducing the need for surgical interventions among patients.
Read more →INOINOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
INOVIO has announced that the FDA has granted Breakthrough Therapy designation for INO-3107, a treatment for Recurrent Respiratory Papillomatosis (RRP). This designation acknowledges the potential of INO-3107 to significantly improve therapy outcomes for patients suffering from this condition. The announcement includes plans for a pivotal trial in early 2024, building on positive data from earlier Phase 1/2 trials. This designation marks a pivotal moment for INOVIO as it seeks to advance its DNA medicine candidate in the fight against HPV-related diseases.
Read more →INO▲ +8.3%on this news
INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference
INOVIO Pharmaceuticals, Inc. announced that Dr. Jacqueline Shea, the President and CEO, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023. During this event, she will lead a company presentation and hold one-on-one meetings with registered investors to discuss INOVIO's advancements in DNA medicines. The conference is a platform for INOVIO to showcase its efforts in treating HPV-related diseases, cancer, and infectious diseases.
Read more →INOINOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug D
INOVIO Pharmaceuticals announced its second quarter 2023 financial results and strategic updates, highlighting plans to commence a Phase 3 trial of INO-3107 aimed at treating recurrent respiratory papillomatosis (RRP) early in 2024. The company received Orphan Drug Designation for INO-3107, emphasizing its commitment to addressing HPV-related diseases. However, INOVIO is halting investments in VGX-3100 for the U.S. market amidst a challenging funding environment, necessitating a reduction in workforce and operational costs to extend its cash runway. The restructuring aims to better align resources with its clinical priorities and improve operational efficiency.
Read more →INOINOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023
INOVIO, a biotechnology firm specializing in DNA medicines for HPV-related diseases and cancer, will release its financial results for the second quarter of 2023 on August 9. This announcement includes a live conference call to discuss the results and provide a business update. The event will feature a Q&A session for analysts, promoting transparency and investor engagement.
Read more →INOINOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
INOVIO Pharmaceuticals announced a proposed settlement regarding stockholder derivative actions, which aims to resolve claims against certain directors and officers. The settlement includes corporate governance reforms and requires court approval. Current stockholders are advised of their rights and the implications of the settlement, including a hearing scheduled for October 11, 2023.
Read more →INOUNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA IN RE INOVIO PHARMACEUTICALS, INC. DERIVATIVE LITIGATION Lead Case No. 2:20-cv-01962-GJP STIPULATION AND AGREEMENT OF SETTLEMENT This Stipulation and Agreemen
In a settlement agreement concerning derivative litigation against Inovio Pharmaceuticals, various plaintiffs allege fiduciary breaches related to the company's COVID-19 vaccine candidate, INO-4800. The settlement is subject to court approval and aims to resolve claims stemming from alleged false and misleading statements made by company executives. Plaintiffs had previously lodged several derivative and class action lawsuits related to securities violations, which have complicated the development timeline of INO-4800. Litigation processes have led to disclosures of internal documents and ongoing legal actions are still pending.
Read more →INOINOVIO to Present at the 2023 Jefferies Healthcare Conference
INOVIO Pharmaceuticals, a biotech company specializing in DNA medicines, announced that its CEO Dr. Jacqueline Shea and CMO Dr. Michael Sumner will present at the 2023 Jefferies Healthcare Conference on June 9, 2023. The presentation will be in a fireside chat format and will include opportunities for one-on-one meetings with investors. A webcast of the presentation will be accessible on INOVIO's investor relations page, with a replay available for 90 days post-event.
Read more →INOINOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
INOVIO Pharmaceuticals announced that the European Commission has granted orphan drug designation for INO-3107, their investigational treatment for Recurrent Respiratory Papillomatosis (RRP). This designation follows a positive opinion from the European Committee for Orphan Medicinal Products, recognizing the need for effective therapies for this debilitating disease. INO-3107 is designed to generate a T cell response against HPV types 6 and 11, which are associated with RRP. The drug also previously received orphan drug designation from the FDA in 2020.
Read more →INOINOVIO Reports First Quarter 2023 Financial Results and Operational Highlights Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial
INOVIO Pharmaceuticals reported its first quarter financial results and highlighted operational advancements, particularly in the development of its DNA medicine candidate, INO-3107, for recurrent respiratory papillomatosis. The company is in alignment with the FDA regarding design elements for the Phase 3 program, and it received a positive opinion for orphan drug designation from European regulators. INOVIO's management emphasized the company’s potential and operational excellence, reinforced by new leadership in regulatory affairs. However, challenges remain, including the uncertainties of clinical trial outcomes and financial viability.
Read more →INONew Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023
INO-3107 is a promising therapeutic candidate for recurrent respiratory papillomatosis (RRP), as presented by INOVIO at COSM 2023. New data from a Phase 1/2 trial indicated that the treatment is well-tolerated and shows potential in reducing the need for surgical interventions among patients. The study demonstrated significant immune responses against HPV types 6 and 11, with a majority of participants experiencing a decrease in surgical interventions in the year following treatment. The positive outcomes from the trial suggest INO-3107 could offer a viable alternative to current standard care for RRP.
Read more →INOINOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference
INOVIO (NASDAQ: INO) has announced that its President and CEO, Dr. Jacqueline Shea, will present at the 2023 RBC Capital Markets Global Healthcare Conference on May 17, 2023. The format includes a fireside chat, and members of INOVIO's management will also conduct one-on-one meetings with registered investors. The company focuses on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, providing a platform for potential future developments in these areas.
Read more →INOINOVIO to Report First Quarter 2023 Financial Results on May 10, 2023
INOVIO Pharmaceuticals, Inc. has announced that it will release its first quarter 2023 financial results on May 10, 2023, after market close. The company will host a live conference call and webcast at 4:30 p.m. ET following the results announcement, which will include a general business update and a Q&A session with analysts. INOVIO continues its focus on developing DNA medicines to combat HPV-associated diseases and cancer.
Read more →INOINOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023
INOVIO Pharmaceuticals announced the acceptance of an abstract for an oral presentation discussing INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) at the COSM 2023. The presentation will take place on May 5, 2023, and will include new safety and immunological data from a recent Phase 1/2 trial. INO-3107 is designed to elicit a targeted T cell response against HPV-6 and HPV-11, which are responsible for RRP, aiming to potentially improve patient outcomes and quality of life.
Read more →INOEuropean Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO
INOVIO announced that the European Committee for Orphan Medicinal Products has issued a positive opinion on the orphan drug designation for its candidate INO-3107, which aims to treat Recurrent Respiratory Papillomatosis (RRP). This rare disease is primarily caused by HPV-6 and HPV-11, leading to potentially life-threatening growths in the respiratory tract. A final decision from the European Commission is anticipated within 30 days. Orphan designation fosters development for treatments of serious conditions affecting a small patient population.
Read more →INO▲ +9.8%on this news
Data from Phase 1b trial with INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) presented at ECCMID 2023
Data from a Phase 1b trial presented at ECCMID 2023 indicates INO-4201 as a promising booster vaccine for rVSV-ZEBOV (Ervebo). The vaccine generated a strong immune response and was well-tolerated among participants. Significant increases in binding and neutralizing antibody titers were observed, suggesting its potential role in extended Ebola protection. The study reinforces INOVIO's commitment to developing countermeasures for infectious diseases.
Read more →INOINOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023
INOVIO announced that an abstract for INO-4201, an Ebola booster vaccine, has been accepted for oral presentation at the ECCMID 2023. The presentation will include data from a completed Phase 1b trial, which focuses on exploring the safety and immunogenicity of INO-4201 when used as a booster for the previously administered rVSV-ZEBOV vaccine. The session is scheduled for April 16, and the results aim to advance understanding of immunity against the Ebola virus, a significant public health concern.
Read more →INOINOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference
INOVIO Pharmaceuticals, a biotechnology company specialized in DNA medicines, announced that its President and CEO, Dr. Jacqueline Shea, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023. The presentation will include a fireside chat format, allowing for insights into the company's developments. Additionally, the management team will engage in one-on-one meetings with registered investors during the conference. A webcast of the event will be available, ensuring broader access to the presentation.
Read more →INOINOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights Announces topline results from REVEAL2, the second Phase 3 trial evaluating VGX-3100 as a treatment for cervical high-grade squam
INOVIO has reported its financial results for Q4 and the full year of 2022, highlighting a strategic transition within the company. Despite not achieving statistical significance in the biomarker-selected population for the VGX-3100 trial, the all-participants population showed promising results. Furthermore, INOVIO's other candidates, including INO-3107 and INO-4201, also displayed positive developments in clinical trials. The company is actively evaluating their candidates' future, focusing on HPV-related treatments.
Read more →INOINOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
INOVIO announced positive preliminary results from the second cohort of its Phase 1/2 trial of INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP). Among the 11 patients treated, 91% experienced a reduction in surgical interventions, with significant median decreases noted compared to the prior year. The treatment was well-tolerated with consistent safety and efficacy which aligns with previous cohort results. INOVIO aims to further develop INO-3107 as a promising therapy against HPV-related conditions.
Read more →INOINOVIO to Report Fourth Quarter and Year-End 2022 Financial Results on March 1, 2023
INOVIO (NASDAQ:INO) is set to release its fourth quarter and year-end 2022 financial results after the market closes on March 1, 2023. The company will host a conference call at 4:30 p.m. ET to discuss these results and provide a business update. INOVIO is focused on developing DNA medicines for HPV-associated diseases, cancer, and infectious diseases, leveraging its proprietary CELLECTRA® device to enhance immune responses.
Read more →INO▲ +7.2%on this newsshared move
INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)
INOVIO has announced positive Phase 1b trial results for INO-4201, a DNA vaccine candidate, as an Ebola booster for individuals previously vaccinated with Ervebo. The trial demonstrated that INO-4201 was well-tolerated, with 100% of participants showing boosted humoral responses. The study involved 46 participants in a randomized, placebo-controlled format and was supported by various organizations including DARPA. Researchers expressed encouragement regarding the vaccine candidate's potential in enhancing immune responses against evolving Ebola virus strains.
Read more →INOINOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates Cost-saving measures include 11% headcount reduction Annual savings expected to be approximately $4.3 million Dat
INOVIO has announced a strategic reorganization aimed at improving operational efficiency and advancing its DNA medicine candidates. The restructuring includes an 11% reduction in the workforce and is expected to save the company approximately $4.3 million annually. The decision follows a review of the company’s portfolio to focus on key programs, particularly INO-3107 for treating Recurrent Respiratory Papillomatosis. Despite the cuts, INOVIO is committed to realizing the potential of its DNA medicines and will provide more financial guidance in March 2023.
Read more →INOINOVIO Provides an Update on Lassa Fever and MERS Programs
PLYMOUTH MEETING, Pa., Nov. 17, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced that it has agreed w
Read more →INOINOVIO Reports Financial Results and Highlights for the Third Quarter 2022 Announced positive interim data for INO-3107 as a potential first-in-class treatment for Recurrent Respiratory Papillomatosis Advanced strategy t
INOVIO Reports Financial Results and Highlights for the Third Quarter 2022 PLYMOUTH MEETING, PA November 8, 2022 INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and disea
Read more →INOINOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800
PLYMOUTH MEETING, Pa., Oct. 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today announced that it has discontin
Read more →INO▲ +9.3%on this news· ran to +28% by day 3shared move
INOVIO to Report Third Quarter 2022 Financial Results on November 8, 2022
PLYMOUTH MEETING, Pa., Oct. 25, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, announced today that third quarter 2
Read more →INOINOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
Treatment with INO-3107 resulted in 16 of 21 (76%) participants with a reduction in number of surgical interventions compared with previous year; 6 participants required no surgical intervention during the trial INO-3107 demonstrated statistical significance based on clinical en
Read more →INOINOVIO to Present at the H.C. Wainwright 24th Annual Global Investment Conference
PLYMOUTH MEETING, Pa., Aug. 30, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced that
Read more →INO▼ -11%on this news
INOVIO Reports Financial Results and Highlights for the Second Quarter 2022 Increased Cash Runway into Third Quarter 2024 with Cost-Savings and Corporate Restructuring Efforts Strengthened Executive Team with Appointment
INOVIO Reports Financial Results and Highlights for the Second Quarter 2022 PLYMOUTH MEETING, PA August 9, 2022 INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people
Read more →INOINOVIO to Report Second Quarter 2022 Financial Results on August 9, 2022
PLYMOUTH MEETING, Pa., July 26, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, announced today that
Read more →INO▲ +9.2%on this news· ran to +21% by day 1
INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients Changes expected to reduce operational expenses and extend the company
INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients PLYMOUTH MEETING, PA, July 19, 2022 INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA
Read more →INO▲ +9.2%on this news· ran to +21% by day 3
INOVIO Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PLYMOUTH MEETING, Pa., July 1, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced that
Read more →INOINOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer
PLYMOUTH MEETING, Pa., June 27, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the
Read more →INO▲ +13.7%on this news
INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022
INOVIO's DNA medicines immunotherapy in combination with Libtayo® elicits vaccine-associated immune responses when administered with RT/TMZ to newly diagnosed GBM patients INO-5401 + INO-9012 + Libtayo® elicits cancer antigen-specific T cells 55% of MGMT methylated subjects rem
Read more →INOINOVIO to Present at Jefferies 2022 Healthcare Conference
PLYMOUTH MEETING, Pa., May 23, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced that
Read more →INO▲ +5.1%on this news· ran to -24% by day 1
INOVIO Reports First Quarter 2022 Financial Results and Program Developments Announces prioritization of heterologous booster strategy for COVID-19 vaccine candidate INO-4800 and discontinuation of Phase 3 INNOVATE trial
INOVIO Reports First Quarter 2022 Financial Results and Program Developments PLYMOUTH MEETING, PA May 10, 2022 INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people
Read more →INO▲ +5.1%on this news· ran to -24% by day 1
INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer
Dr. Shea brings more than 25 years of leadership and industry expertise in life sciences and biotech PLYMOUTH MEETING, Pa., May 10, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people f
Read more →INOINOVIO to Report First Quarter 2022 Financial Results on May 10, 2022
PLYMOUTH MEETING, Pa., April 26, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that first quarter 2022 financial results will be released after the market close on May 10, 2022. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET
Read more →INOINOVIO to Present at Oppenheimer
PLYMOUTH MEETING, Pa., March 8, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases, today announced
Read more →INOINOVIO Reports Fourth Quarter 2021 and Year-End Financial Results
PLYMOUTH MEETING, Pa., March 1, 2022 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases, today reported
Read more →INO▲ +6.1%on this news
INOVIO to Report Fourth Quarter and Year-End 2021 Financial Results on March 1, 2022
PLYMOUTH MEETING, Pa., Feb. 15, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that fourth quarter 2021 financial results will be released after the market close on March 1, 2022. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. E
Read more →INOINOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18
PLYMOUTH MEETING, Pa., Dec. 14, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced updates
Read more →INOINOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants
PLYMOUTH MEETING, Pa., Nov. 30, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced the compa
Read more →INOINOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201
PLYMOUTH MEETING, Pa., Nov. 16, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that severa
Read more →INOINOVIO to Give Eight Presentations at the 34th International Papillomavirus Conference
PLYMOUTH MEETING, Pa., Nov. 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases, and help treat cancer, and HPV-associated diseases, announced today th
Read more →INOINOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.
PLYMOUTH MEETING, Pa., Nov. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced that the U
Read more →INOINOVIO Reports Third Quarter 2021 Financial Results
PLYMOUTH MEETING, Pa., Nov. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat people with cancer, and HPV-associated diseases, today
Read more →INO▼ -5.5%on this newsshared move
INOVIO Expands Executive Leadership to Prepare for Commercial Operations
PLYMOUTH MEETING, Pa., Nov. 5, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the strategi
Read more →INOINOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India
PLYMOUTH MEETING, Pa., Nov. 3, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases, and help treat cancer, and HPV-associated diseases, today announced tha
Read more →INOINOVIO to Report Third Quarter 2021 Financial Results on November 9, 2021
PLYMOUTH MEETING, Pa., Oct. 27, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that third quarter 2021 financial results will be released after the market close on November 9, 2021. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m.
Read more →INOINOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa
PLYMOUTH MEETING, Pa., Oct. 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced its Phase 1
Read more →INOINOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives
PLYMOUTH MEETING, Pa., Oct. 21, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the signing
Read more →INOINOVIO Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800
PLYMOUTH MEETING, Pa., Oct. 12, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the online p
Read more →INOINOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization
PLYMOUTH MEETING, Pa., Oct. 11, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it has
Read more →INOINOVIO to Present Three Posters at IDWeek 2021
PLYMOUTH MEETING, Pa., Sept. 29, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, will present three
Read more →INOINOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico
PLYMOUTH MEETING, Pa., Sept. 22, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it has
Read more →INOINOVIO to Present at Upcoming Investor Conferences in September
PLYMOUTH MEETING, Pa., Sept. 1, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that Dr. J.
Read more →INOINOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800
PLYMOUTH MEETING, Pa., Aug. 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it has
Read more →INO▲ +5.4%on this news
INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO
PLYMOUTH MEETING, Pa. and SUZHOU, China, Aug. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today annou
Read more →INO▲ +5.4%on this news
INOVIO Reports Second Quarter 2021 Financial Results
PLYMOUTH MEETING, Pa., Aug. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financ
Read more →INOINOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease
PLYMOUTH MEETING, Pa., Aug. 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that the company has do
Read more →INOINOVIO to Report Second Quarter 2021 Financial Results on August 9, 2021
PLYMOUTH MEETING, Pa., July 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that second quarter 2021 financial results will be released after the market close on August 9, 2021. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m.
Read more →INOINOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800 Phase 3 efficacy trial planned to commence this summer in areas of the world underserved by v
INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Phase 3 efficacy trial planned to commence this summer in areas of the world underserved News follows recently announced Phase 2 data, which showed INO-4800 to be well-tol
Read more →INOINOVIO to Present at the Jefferies 2021 Virtual Healthcare Conference
PLYMOUTH MEETING, Pa., May 25, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO) a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, announced today that Dr. Josep
Read more →INOINOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors Dr. Dansey, Seagen s Chief Medical Officer, brings extensive expertise in immuno-oncology and drug development Appointment of industry leader
INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors Dr. Dansey, Seagen s Chief Medical Officer, brings extensive expertise in immuno-oncology and drug development Appointment of industry leader in drug development expands the Board s diverse industr
Read more →INOINOVIO's Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from...
PLYMOUTH MEETING, Pa., May 12, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that its next
Read more →INOINOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine
PLYMOUTH MEETING, Pa., May 10, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced positive safe
Read more →INOINOVIO Reports First Quarter 2021 Financial Results
PLYMOUTH MEETING, Pa., May 10, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financ
Read more →INOINOVIO to Present at Upcoming Investor Conferences in May
PLYMOUTH MEETING, Pa., May 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that INOVIO ma
Read more →INOINOVIO to Report First Quarter 2021 Financial Results on May 10, 2021
PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after the market close on May 10, 2021. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET
Read more →INOINOVIO Planning for ex-US Global Phase 3 Trial for INO-4800
PLYMOUTH MEETING, Pa., April 23, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it is
Read more →INOINOVIO's COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from...
PLYMOUTH MEETING, Pa., April 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, and cancer, today announced the results of a study focus
Read more →INOINOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel
PLYMOUTH MEETING, Pa., March 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the appointment of Michael Cordera as
Read more →INOINOVIO to Present at Upcoming Investor Conferences in March
PLYMOUTH MEETING, Pa., March 4, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that Dr. J. Joseph Kim, President and
Read more →INOINOVIO Reports Fourth Quarter 2020 And Year-End Financial Results Investor Call Today at 4:30
INOVIO Reports Fourth Quarter 2020 And Year-End Financial Results Investor Call Today at 4:30 PM ET MEETING, PA March 1, 2021 INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from in
Read more →INOINOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18
PLYMOUTH MEETING, Pa., March 1, 2021 /PRNewswire/ -- INOVIO, (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and HPV-associated diseases, today announced it met prima
Read more →INOINOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO
PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, Feb. 24, 2021 /PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to
Read more →INOINOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa
PLYMOUTH MEETING, Pa., Feb. 23, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the first participant was dosed in a P
Read more →INOINOVIO to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021
PLYMOUTH MEETING, Pa., Feb. 16, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that fourth quarter and year-end 2020 financial results will be released after the market close on March 1, 2021. Following the release, INOVIO will host a live conference call and webcast a
Read more →INOINOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters
PLYMOUTH MEETING, Pa., Jan. 25, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associa
Read more →INOIn the preliminary prospectus supplement to be used in connection with a proposed public offering of shares of its common stock by Inovio Pharmaceuticals, Inc. (the Company ), the Company provided the following updates o
In the preliminary prospectus supplement to be used in connection with a proposed public offering of shares of its common stock by Inovio Pharmaceuticals, Inc. (the Company ), the Company provided the following updates or supplements to the description of certain aspects of the
Read more →INOINOVIO Announces Proposed Public Offering of Common Stock
INOVIO Announces Proposed Public Offering of Common Stock PLYMOUTH MEETING, Pa., January 20, 2021 (Globe Newswire) INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from
Read more →INOINOVIO Announces Pricing of Public Offering of Common Stock
PLYMOUTH MEETING, Pa., Jan. 20, 2021 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associa
Read more →INOINOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18 INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from...
PLYMOUTH MEETING, Pa., Jan. 6, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and HPV-associated diseases, today announced positive effic
Read more →INOINOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China Partnership Adds Asian Manufacturing Resource to INOVIO s Global Manufacturing Consortium fo
INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China Partnership Adds Asian Manufacturing Resource to INOVIO s Global Manufacturing Consortium for INO-4800 INO-4800 Phase 2 Trial Fully Enrolled in Chi
Read more →INOINOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet
PLYMOUTH MEETING, Pa., Dec. 24, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the publication of peer-reviewed Phase
Read more →INOINOVIO to Develop DNA-encoded Monoclonal Antibody (dMAb®) Candidates to Treat COVID-19 with Funding from the Defense Advanced Research Projects Agency (DARPA) and the Department of Defense
PLYMOUTH MEETING, Pa., Dec. 15, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the company and a team of scientists f
Read more →INOINOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China
PLYMOUTH MEETING, Pa. and SUZHOU, China, Dec. 10, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Su
Read more →INOINOVIO's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Anal Dysplasia Caused by HPV-16/18 INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from...
PLYMOUTH MEETING, Pa., Dec. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and diseases associated with HPV, today announced positive
Read more →INOINOVIO Doses First Subject in Phase 2 Segment of its INNOVATE Phase 2/3 Clinical Trial for INO-4800, its DNA Medicine to Prevent COVID-19
PLYMOUTH MEETING, Pa., Dec. 7, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced it has dosed its first subject in a Ph
Read more →INOINOVIO Expands Global Manufacturing Consortium For Its COVID-19 Vaccine Candidate INO-4800 With Addition of Kaneka Eurogentec S.A.
PLYMOUTH MEETING, Pa., Dec. 3, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the execution of an agreement with Kane
Read more →INOINOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)
PLYMOUTH MEETING, Pa., Nov. 23, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced it has dosed its first subject with D
Read more →INOINOVIO Presents Clinical Results of its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual Meeting
PLYMOUTH MEETING, Pa., Nov. 20, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, announced today that data from the company's
Read more →INOINOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense
INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Funded by the U.S. Department of Defense PLYMOUTH MEETING, PA November 16, 2020 INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to
Read more →INOINOVIO Reports Third Quarter 2020 Financial Results
PLYMOUTH MEETING, Pa., Nov. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today reported financial results for the quarte
Read more →INOINOVIO to Report Third Quarter 2020 Financial Results on November 9, 2020
PLYMOUTH MEETING, Pa., Oct. 26, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that third quarter 2020 financial results will be released after the market close on November 9, 2020. Following the release, the Company will host a live conference call and webcast at 4:30
Read more →INOINOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 / 3 Trial of COVID-19 Vaccine Candidate INO-4800
INOVIO Reports FDA Partial Clinical Hold for Planned Phase 2 / 3 Trial of COVID-19 Vaccine Candidate INO-4800 PLYMOUTH MEETING, PA September 28, 2020 INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protec
Read more →INOINOVIO Adds Thermo Fisher Scientific To Global Manufacturing Consortium
PLYMOUTH MEETING, Pa., Sept. 8, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that Thermo Fisher Scientific, the wor
Read more →INOINOVIO Reports Second Quarter 2020 Financial Results; Provides DNA Medicines Clinical Program Mid-Year Update
PLYMOUTH MEETING, Pa., Aug. 10, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today reported financial results for the quart
Read more →INOINOVIO's COVID-19 DNA Vaccine INO-4800 Provides Protection with Memory Immune Responses In Non-Human Primates Challenged with SARS-CoV-2 Virus INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from...
PLYMOUTH MEETING, Pa., July 30, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that its COVID-19 DNA vaccine
Read more →INOINOVIO Receives Orphan Drug Designation From U.S. FDA for DNA Medicine INO-3107 To Treat Rare Disease Recurrent Respiratory Papillomatosis (RRP)
PLYMOUTH MEETING, Pa., July 29, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for INO-3107, its DNA medicine being evaluated in a Phase 1/2 trial for treatment of recurrent respiratory pa
Read more →INOINOVIO to Report Second Quarter 2020 Financial Results on August 10, 2020
PLYMOUTH MEETING, Pa., July 27, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that second quarter 2020 financial results will be released after the market close on August 10, 2020. Following the release, the Company will host a live conference call and webcast at 4:30
Read more →INOINOVIO Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19
PLYMOUTH MEETING, Pa., June 30, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to protect and treat people from infectious diseases and cancer, today announced positive interim clinical data
Read more →INOINOVIO Expands Senior Management Team
PLYMOUTH MEETING, Pa., June 25, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced it has appointed two experienced senior executives to lead its growth in the Asia market and to advance the clinical development of its DNA vaccine INO-4800 to combat the COVID-19 pandemic.
Read more →INOINOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA 3PSP Smart Device and Procurement of CELLECTRA 2000 for COVID-19 DNA Vaccine U.S. Government will support the scal
INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA 3PSP Smart Device and Procurement of CELLECTRA 2000 for COVID-19 DNA Vaccine PLYMOUTH MEETING, PA June 23, 2020 INOVIO (NASDAQ:INO) today announced it has received $71 mi
Read more →INOINOVIO and IVI Partner with Seoul National University Hospital to Start Phase 1/2 Clinical Trial of INOVIO
SEOUL, South Korea and PLYMOUTH MEETING, Pa., June 4, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), the International Vaccine Institute (IVI), and Seoul National University Hospital announced a partnership to start a Phase 1/2 clinical trial of INOVIO's COVID-19 vaccine INO-4800 in
Read more →INOINOVIO to Host Webinar "DNA Medicines: From COVID-19 to Cancer"
PLYMOUTH MEETING, Pa., May 26, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to protect and treat people from infectious diseases, cancer, and diseases associated with HPV, today announced
Read more →INOINOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models INOVIO (NASDAQ:INO) today announced the publication of the preclinical study data for IN0-4800, its COVID-19 DNA vaccine, demonstrating robust...
PLYMOUTH MEETING, Pa., May 20, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced the publication of the preclinical study data for IN0-4800, its COVID-19 DNA vaccine, demonstrating robust neutralizing antibody and T cell immune responses against coronavirus SARS-CoV-2. The
Read more →INOINOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment INOVIO (NASDAQ: INO) today announced that 85 percent (44 out of 52) of patients newly diagnosed with the deadly brain cancer glioblastoma multiforme...
PLYMOUTH MEETING, Pa., May 14, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) today announced that 85 percent (44 out of 52) of patients newly diagnosed with the deadly brain cancer glioblastoma multiforme (GBM) who received the company's DNA medicine INO-5401, in combination with INO
Read more →INOINOVIO to Present at RBC Capital Markets Virtual Global Healthcare Conference
PLYMOUTH MEETING, Pa., May 12, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President and CEO, along with other members of management will present in a fireside discussion at the RBC Capital Markets Global Healthcare Conference on Tuesday, May
Read more →INOINOVIO Reports First Quarter 2020 Financial Results; Provides Business Update
PLYMOUTH MEETING, Pa., May 11, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to protect and treat people from infectious diseases, cancer, and diseases associated with HPV, today reported
Read more →INOINOVIO DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Inovio Pharmaceuticals, Inc. To Contact The Firm
NEW YORK, May 09, 2020 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ:INO) of the May 12, 2020 deadline to seek the role of lead plaintiff in a federal securit
Read more →INOINOVIO Expands Manufacturing of COVID-19 DNA Vaccine INO-4800 With New Funding from CEPI
PLYMOUTH MEETING, Pa., April 30, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced it has entered into an agreement to expand its manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH & Co. KG, to support large-scale manufacturing of I
Read more →INOINOVIO Completes Enrollment in the Phase 1 U.S. Trial of INO-4800 for COVID-19 DNA Vaccine; Interim Results Expected in June
PLYMOUTH MEETING, Pa., April 28, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced that its Phase 1 U.S. clinical trial for COVID-19 DNA vaccine INO-4800 is fully enrolled with all 40 healthy volunteers receiving their first dose, with interim immune responses and safety r
Read more →INOINOVIO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at the American Society of Gene & Cell Therapy (ASGCT) Conference
PLYMOUTH MEETING, Pa. and SEOUL, South Korea, April 28, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) and GeneOne Life Science (KSE:011000) today announced interim data through week 16 from a Phase 1/2a trial of DNA vaccine INO-4700 (also called GLS-5300) for MERS coronavirus (MERS-Co
Read more →INOINOVIO to Report First Quarter 2020 Financial Results on May 11, 2020
PLYMOUTH MEETING, Pa., April 27, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) announced today that first quarter 2020 financial results will be released after the market close on May 11, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m
Read more →INOIVI, INOVIO, and KNIH to Partner with CEPI in Phase 1/2 Clinical Trial of INOVIO
PLYMOUTH MEETING, Pa. and SEOUL, South Korea, April 16, 2020 /PRNewswire/ -- The International Vaccine Institute (IVI) announced today that the Coalition for Epidemic Preparedness Innovations (CEPI) has granted $6.9 million funding to INOVIO (NASDAQ:INO) to work with IVI and the
Read more →INOINOVIO to Host its Annual Meeting of Stockholders in Virtual Format and at a New Time
PLYMOUTH MEETING, Pa., April 15, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced that due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and recommendations and orders from federal and state governmenta
Read more →INOINOVIO Initiates Phase 1 Clinical Trial Of Its COVID-19 Vaccine and Plans First Dose Today
PLYMOUTH MEETING, Pa., April 6, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the U.S. Food and Drug Administration has accepted the company's Investigational New Drug (IND) application for INO-4800, its DNA vaccine candidate designed to prev
Read more →INOINOVIO Interim Results of an Open-Label Phase 2 Trial of VGX-3100 Show Efficacy Against HPV-associated Vulvar Dysplasia
PLYMOUTH MEETING, Pa., March 30, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) today reported interim results from an open-label Phase 2 trial designed to evaluate the safety and efficacy of VGX-3100 in women with vulvar dysplasia, also known as high grade squam
Read more →INOINOVIO Reports Positive Interim Phase 2 VGX-3100 Results In Patients with HPV-associated Anal Dysplasia
PLYMOUTH MEETING, Pa., March 26, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) today announced positive interim results from an open-label, Phase 2 study showing its lead DNA medicine candidate VGX-3100 to be safe and effective in treating men and women with ana
Read more →INOOlogy Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Million Department of Defense Grant
PLYMOUTH MEETING, Pa. and ALACHUA, Fla., March 24, 2020 /PRNewswire/ -- Ology Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), and Inovio Pharmaceuticals Inc., (NASDAQ: INO) developing DNA medicines for infectious diseases and cancer, anno
Read more →INOINOVIO PHARMACEUTICALS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Inovio Pharmaceuticals, Inc.
LEAD PLAINTIFF DEADLINE IS MAY 12, 2020 NEW YORK, March 17, 2020 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) in the United State
Read more →INOINOVIO Pharmaceuticals Reports 2019 Fourth Quarter and Year-End Financial Results
PLYMOUTH MEETING, Pa., March 12, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with HPV, cancer, and infec
Read more →INOINOVIO Receives New $5 Million Grant to Accelerate Scale Up of Smart Delivery Device for Its COVID-19 Vaccine
PLYMOUTH MEETING, Pa., March 12, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has received a new $5 million grant from the Bill & Melinda Gates Foundation to accelerate the testing and scale up of CELLECTRA® 3PSP proprietary smart device
Read more →INOInovio Pharmaceuticals Investors Who Have Lost Money Should Contact Block & Leviton
BOSTON, March 10, 2020 (GLOBE NEWSWIRE) -- National securities litigation firm Block & Leviton (www.blockesq.com) is investigating potential claims against Inovio Pharmaceuticals (NASDAQ: INO) and certain of its officers for securities fraud. Investors who have lost money are enc
Read more →INOInovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800
PLYMOUTH MEETING, Pa., March 3, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced an accelerated timeline for developing its DNA vaccine INO-4800 to address COVID-19, the respiratory infection the World Health Organization (WHO) has designated a Publi
Read more →INOInovio Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
PLYMOUTH MEETING, Pa., March 2, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that fourth quarter and full year 2019 financial results will be released after the market close on March 12, 2020. Following the release, the Company will host a live
Read more →INOInovio Receives Authorization from the U.S. FDA To Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine To Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)
PLYMOUTH MEETING, Pa., Feb. 10, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate its DNA medicine INO-3107 in a Phase 1/2 trial for t
Read more →INOInovio Publishes Patient Benefit Results From A Pilot Clinical Study in Recurrent Respiratory Papillomatosis (RRP), A Rare Disease Caused by HPV Infections
PLYMOUTH MEETING, Pa., Feb. 3, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced publication of data from its pilot clinical study of INO-3106, a novel DNA therapy targeting human papilloma virus type 6 (HPV 6) for the treatment of recurrent respirat
Read more →INOInovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China
PLYMOUTH MEETING, Pa., Jan. 30, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that it is collaborating with Beijing Advaccine Biotechnology Co. to advance the development in China of INO-4800, Inovio's vaccine against the recently emerged strain
Read more →INOInovio Selected by CEPI to Develop Vaccine Against New Coronavirus
PLYMOUTH MEETING, Pa., Jan. 23, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to $9 million to develop a vaccine against the recently emerged strain of cor
Read more →INOInovio Welcomes Biotech Leader to its Board of Directors
PLYMOUTH MEETING, Pa., Jan. 15, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the appointment of Jay Shepard to its Board of Directors. Mr. Shepard brings broad healthcare and financial experience to the board given his tenure as CEO of several bi
Read more →INOInvestors: Ben Matone, 484-362-0076, ben.matone@inovio.com Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com Inovio Welcomes Biotech Leader To its Board of Directors Inovio also announces retirement
Investors: Ben Matone, 484-362-0076, ben.matone@inovio.com Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com Welcomes Biotech Leader To its Board of Directors Inovio also announces retirement of long-serving board member PLYMOUTH MEETING, PA January 15, 2020 Ino
Read more →INOInovio Provides Update on Clinical Program Plans for 2020
PLYMOUTH MEETING, Pa., Jan. 6, 2020 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that Inovio's President & CEO, Dr. J. Joseph Kim will present a corporate update of the company's clinical program goals for 2020 at the Biotech Showcase 2020 Conference in San
Read more →INOInovio Pharmaceuticals to Present at the 2019 Piper Jaffray 31st Annual Healthcare Conference
PLYMOUTH MEETING, Pa., Nov. 25, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that Dr. J. Joseph Kim, President and CEO, will present in a fireside discussion at the Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4, 2019 a
Read more →INOInovio Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference
PLYMOUTH MEETING, Pa., Nov. 15, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that Dr. J. Joseph Kim, President and CEO, will present in a fireside discussion at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 10:20 a.m. Ea
Read more →INOInovio Pharmaceuticals Reports 2019 Third Quarter Financial Results
PLYMOUTH MEETING, Pa., Nov. 12, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO), an innovative biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases, today reported
Read more →INOInovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab)
80% of Methylated Patients and 75% of Unmethylated Patients Were Disease Progression-Free at 6 Months PLYMOUTH MEETING, Pa., Nov. 5, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today positive interim results from Inovio's Phase 2 study (NCT03491683)
Read more →INOInovio Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019
PLYMOUTH MEETING, Pa., Oct. 29, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that third quarter 2019 financial results will be released after the market close on November 12, 2019. Following the release, the Company will host a conference call a
Read more →INOInovio Receives NIH Funding to Target its dMAb® Technology Against Antimicrobial-Resistant Infection
PLYMOUTH MEETING, Pa., Sept. 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that the company and its collaborator The Wistar Institute have received a $4.6 million National Institutes of Health (NIH) grant in support of innovative research to
Read more →INOInovio Pharmaceuticals to Present at Upcoming Investor Conferences
PLYMOUTH MEETING, Pa., Sept. 3, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that Joseph Kim, President and CEO, will present an Inovio overview and business update at two upcoming investor conferences: H.C. Wainwright 21st Annual Global Invest
Read more →INOInovio Completes Enrollment of its VGX-3100 Open-label Phase 2 Trial for Treatment of HPV-Related High-Grade Anal Dysplasia
PLYMOUTH MEETING, Pa., Aug. 19, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it has completed enrollment in the company's open-label, 24 patient, Phase 2 trial with its lead immunotherapy product VGX-3100 in patients with precancerous lesio
Read more →INOInovio Pharmaceuticals Reports 2019 Second Quarter Financial Results
PLYMOUTH MEETING, Pa., Aug. 8, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO), an innovative biotechnology company focused on the discovery, development and commercialization of synthetic DNA technology targeted against cancers and infectious diseases, today repo
Read more →INOInovio Closes $15 Million Private Placement of Convertible Bonds to Institutional Investors in Korea
PLYMOUTH MEETING, Pa., Aug. 6, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the closing of a private placement in the form of convertible bonds with an aggregate principal amount of 18 billion Korean Won (KRW) (approximately USD $15 million base
Read more →INOEXECUTION VERSION Inovio Pharmaceuticals, Inc. KRW18,000,000 1.00% Convertible Bonds due 2024 Registration Rights Agreement
Pharmaceuticals, Inc. KRW18,000,000 1.00% Convertible Bonds due 2024 Registration Rights Agreement Each of the Holders listed on Schedule A Ladies and Gentlemen: Inovio Pharmaceuticals, Inc., a Delaware corporation (the Company ), proposes to issue and sell to you, its 1.00
Read more →INOInovio Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 8, 2019
PLYMOUTH MEETING, Pa., July 30, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that second quarter 2019 financial results will be released after the market close on August 8, 2019. Following the release, the company will host a conference call and
Read more →INOInovio's Positive First-in-Human MERS Vaccine Results Published in The Lancet Infectious Diseases Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that positive results from the first-in-human trial of its vaccine against the Middle East ...
PLYMOUTH MEETING, Pa., July 25, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that positive results from the first-in-human trial of its vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS) were published in The Lancet Infectio
Read more →INOInovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates
PLYMOUTH MEETING, Pa., July 16, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it has sharpened its corporate strategy to focus on the commercial development of its late-stage HPV assets and reallocate capital to develop fast-to-market produc
Read more →INOInvestors: Ben Matone, 484-362-0076, ben.matone@inovio.com Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com Inovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates Compan
Investors: Ben Matone, 484-362-0076, ben.matone@inovio.com Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com Inovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates Company Cuts Selected Early-Stage R&D Programs, Burn-Rate by 25%, Host
Read more →INOInovio Completes Enrollment of VGX-3100 Phase 2 Trial for the Treatment of HPV-Related Vulvar Dysplasia (VIN)
PLYMOUTH MEETING, Pa., July 8, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has completed enrollment in its Phase 2 trial with VGX-3100 in patients with precancerous lesions of the vulva or vulvar intraepithelial neoplasia (VIN). VGX-3100
Read more →INOInovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer
PLYMOUTH MEETING, Pa., June 26, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the completion of target enrollment of 198 participants for its pivotal Phase 3 registration trial ("REVEAL 1") of VGX-3100, a novel DNA-based immunotherapy being teste
Read more →INOInovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device
PLYMOUTH MEETING, Pa., June 10, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the medical arm of the U.S. Defense Threat Reduction Agency (DTRA) will fund the further development of Inovio's new commercial intradermal delivery device. DTRA's
Read more →INOInovio First to Advance Lassa Fever Candidate Vaccine Into a Clinical Trial
PLYMOUTH MEETING, Pa. and OSLO, Norway, May 21, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO), together with CEPI, today announced it has dosed subjects in a Phase 1, first-in-human clinical trial to evaluate INO-4500, its DNA candidate vaccine to prevent infect
Read more →INOInovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio
PLYMOUTH MEETING, Pa. and GERMANTOWN, Md. and HILDEN, Germany, May 16, 2019 /PRNewswire/ -- Inovio Pharmaceuticals Inc. (NASDAQ: INO) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to co-develop a diagnostic test to identify patients m
Read more →INOInovio and Plumbline Life Sciences Establish Animal Health Collaboration to Develop A Novel Vaccine Against Deadly African Swine Fever Virus
PLYMOUTH MEETING, Pa. and SEOUL, South Korea, May 15, 2019 /PRNewswire/ -- Inovio Pharmaceuticals Inc. (NASDAQ: INO) and Plumbline Life Sciences (XKRX: 222670) today announced a collaboration to co-develop a novel animal health vaccine for African swine fever (ASF) virus. The vac
Read more →INOInovio Pharmaceuticals Reports 2019 First Quarter Financial Results
PLYMOUTH MEETING, Pa., May 9, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO), an innovative biotechnology company focused on the discovery, development and commercialization of its synthetic nucleic technology targeted against cancers and infectious diseases, tod
Read more →INOInovio Receives European Medicines Agency Certification For Quality and Non-Clinical Data for Its Phase 3 Product, VGX-3100
PLYMOUTH MEETING, Pa., May 6, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that its lead Phase 3 product candidate, VGX-3100, has been granted an Advanced Therapy Medicinal Product Certificate for quality and non-clinical data. The procedure of
Read more →INOInovio Pharmaceuticals to Report First Quarter 2019 Financial Results on May 9, 2019
PLYMOUTH MEETING, Pa., May 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that first quarter 2019 financial results will be released after the market close on May 9, 2019. Following the release, the Company will host a conference call and live
Read more →INOInovio Publishes Cancer Killing Data of Its Transformative DNA-encoded Bi-specific T Cell Engagers (dBiTEs™) in a Peer-reviewed Journal
PLYMOUTH MEETING, Pa., April 18, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the company's novel DNA-encoded Bi-specific T Cell Engagers (dBiTEs) generated potent anti-tumor activities and cleared established tumors in preclinical studies. Inov
Read more →INOInovio's Phase 3 HPV Immunotherapy Selected As Best Therapeutic Vaccine at World Vaccine Congress Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that VGX-3100, its Phase 3 immunotherapy to treat cervical dysplasia, was recognized as...
PLYMOUTH MEETING, Pa., April 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that VGX-3100, its Phase 3 immunotherapy to treat cervical dysplasia, was recognized as "Best Therapeutic Vaccine" at the World Vaccine Congress held this week in Washi
Read more →INOInovio Achieves Third Cancer Indication Milestone for MEDI0457 Phase 2 Development
PLYMOUTH MEETING, Pa., April 8, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it achieved a third indication milestone from AstraZeneca resulting from dosing a patient in a Phase 2 combination trial evaluating MEDI0457 (formerly called INO-3
Read more →INOInovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors in Pilot Clinical Study Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its novel therapy INO-3106 against the human papilloma virus type 6 (HPV 6) demonstrated...
PLYMOUTH MEETING, Pa., April 3, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its novel therapy INO-3106 against the human papilloma virus type 6 (HPV 6) demonstrated clinical efficacy in a study of two patients with recurrent respiratory papillom
Read more →INOInovio Presents Cancer Killing Data of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) at AACR
PLYMOUTH MEETING, Pa., April 2, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the company's novel DNA-Encoded Bi-specific T Cell Engagers (dBiTEs™) generated potent anti-tumor activities in a preclinical study. Results were presented as a poster
Read more →INOInovio Completes Enrollment Ahead of Schedule In Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron
PLYMOUTH MEETING, Pa., April 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that its Phase 1/2 immuno-oncology trial in patients with newly diagnosed glioblastoma (GBM) has completed its enrollment three months ahead of schedule. The 52-patient
Read more →INOInovio Pharmaceuticals to Present at H.C. Wainwright Global Life Sciences Conference in London, UK
PLYMOUTH MEETING, Pa., March 27, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Monday, April 8, 2019 at 4:10 p.m. local time. The conference is being held at t
Read more →INOInvestors: Ben Matone, Inovio, 484-362-0076, ben.matone@inovio.com Media: Jeff Richardson, Inovio, 267-440-4211, jrichardson@inovio.com Inovio Appoints Global Commercial Leader to its Board of Directors
CONTACTS: Investors: Ben Matone, Inovio, 484-362-0076, ben.matone@inovio.com Media: Jeff Richardson, Inovio, 267-440-4211, jrichardson@inovio.com Inovio Appoints Global Commercial Leader to its Board of Directors MEETING, PA March 25, 2019 Inovio Pharmaceuticals, Inc. (NASDA
Read more →INOInovio Appoints Global Commercial Leader to its Board of Directors
PLYMOUTH MEETING, Pa., March 25, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Dr. Ann C. Miller to its Board of Directors. Dr. Miller had an outstanding marketing career launching and building blockbuster products for Merck, A
Read more →INOInovio's Ebola Vaccine Delivered Intradermally Demonstrates 100% Immunogenicity in a Clinical Study Published in The Journal of Infectious Diseases Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and...
PLYMOUTH MEETING, Pa., March 21, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses. This Phase 1 data was published in The Journal of Infectious
Read more →INOInovio Pharmaceuticals Reports 2018 Fourth Quarter and Year-End Financial Results
PLYMOUTH MEETING, Pa., March 12, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a late-stage biotechnology company focused on the development and commercialization of DNA immunotherapies targeted against cancers and infectious diseases, today reported financial r
Read more →INOInovio Appoints Chief Operating Officer; Announces Strategic Management Changes
PLYMOUTH MEETING, Pa., March 12, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Jacqueline E. Shea, PhD, as Inovio's Chief Operating Officer (COO) and Executive Vice President. Dr. Shea is an experienced life sciences senior exe
Read more →INOInvestors: Ben Matone, Inovio, 484-362-0076, ben.matone@inovio.com Media: Jeff Richardson, Inovio, 267-440-4211, jrichardson@inovio.com Inovio Appoints Chief Operating Officer; Announces Strategic Management Ch
Inovio Appoints Chief Operating Officer; Announces Strategic Management Changes PLYMOUTH MEETING, PA March 12, 2019 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Jacqueline E. Shea, PhD, as Inovio s Chief Operating Officer (COO) and Executive Vi
Read more →INOInovio Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 12, 2019
PLYMOUTH MEETING, Pa., March 5, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that 2018 fourth quarter and full year financial results will be released after the market close on March 12, 2019. Following the release, the Company will host a live
Read more →INOInovio Initiates REVEAL 2 Global Phase 3 Clinical Study For the Treatment of HPV-Related Cervical Pre-cancer
PLYMOUTH MEETING, Pa., March 4, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the initiation and opening of sites to enroll the second portion of the company's Phase 3 program for VGX-3100, Inovio's DNA-based immunotherapy to treat cervical dyspl
Read more →INOInovio Pharmaceuticals Completes Sale of Additional Convertible Senior Notes
PLYMOUTH MEETING, Pa., March 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the sale of additional 6.50% convertible senior notes due 2024 (the "notes"), bringing the total amount of notes sold to $78.5 million in aggregate principal amount. Th
Read more →INOInovio Announces First Subject Dosed with its DNA-Encoded Monoclonal Antibody (dMAb™) In First-Ever Human Trial
PLYMOUTH MEETING, Pa., Feb. 20, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) in collaboration with The Wistar Institute and the University of Pennsylvania announced today that the first subject was dosed as part of the first-ever human study of Inovio's DNA-enc
Read more →INOInovio Pharmaceuticals Prices $65.0 Million Convertible Senior Notes Offering
Inovio Pharmaceuticals Prices Convertible Senior Notes Offering PLYMOUTH MEETING, Pa., February 14, 2019 Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today the pricing of its offering of $65.0 million aggregate principal amount of 6.50% convertible senior notes due 2024
Read more →INOInovio Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
Inovio Pharmaceuticals Announces Proposed Convertible Senior Notes Offering PLYMOUTH MEETING, Pa., February 13, 2019 Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today its intention to offer, subject to market and other conditions, $65 million aggregate principal amount
Read more →INOInovio Reports 2nd Patient Achieving Full Remission from HPV-Related Head & Neck Cancer after Treatment with Synthetic DNA Vaccine and a PD-1 Checkpoint Inhibitor
PLYMOUTH MEETING, Pa., Jan. 24, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that a second patient with HPV-related head and neck cancer treated with INO-3112 (now called MEDI0457) in a Phase 1 trial achieved a sustained complete response (full
Read more →INOInovio's dMAb™ PD-1 Checkpoint Inhibitors Demonstrate Higher and More Prolonged Expression Compared to Native Pembrolizumab and Nivolumab Sequences In Preclinical Studies Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the successful development of optimized DNA-encoded monoclonal antibodies (dMAbs™)...
PLYMOUTH MEETING, Pa., Jan. 15, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the successful development of optimized DNA-encoded monoclonal antibodies (dMAbs™) targeting the immune checkpoint molecule PD-1. The breakthrough preclinical data demo
Read more →INOInovio's DNA-Encoded Monoclonal Antibody (dMAb™) Platform Leaps Forward with First-in-Human Trial Inovio Pharmaceuticals, Inc. (NASDAQ: INO) in collaboration with The Wistar Institute and the University of Pennsylvania announced today the...
PLYMOUTH MEETING, Pa., Jan. 7, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) in collaboration with The Wistar Institute and the University of Pennsylvania announced today the initiation of the first human study of its DNA-encoded monoclonal antibody (dMAb™) tech
Read more →INOInovio Announces Appointments to its Board of Directors
PLYMOUTH MEETING, Pa., Jan. 3, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that Mr. Simon X. Benito, former Merck Vaccines executive, has been appointed Chairman of Inovio's Board of Directors, replacing Dr. Avtar Dhillon who is retiring from t
Read more →INOInvestors: Ben Matone, 484-362-0076, ben.matone@inovio.com Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com Inovio Announces Appointments to its Board of Directors Simon X. Benito, Director Since 20
Investors: Ben Matone, 484-362-0076, ben.matone@inovio.com Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com Inovio Announces Appointments to its Board of Directors Simon X. Benito, Director Since 2003, Named Chairman of the Board; Lota Zoth, former MedImmune CFO,
Read more →INOInovio Announces Initiation of “MD Anderson’s HPV-Related Cancers Moon Shot” Phase 2 Trial in New HPV Indications
Inovio Pharmaceuticals has initiated a Phase 2 trial evaluating MEDI0457 in combination with durvalumab for HPV-related cancers. This trial, part of MD Anderson's Moon Shot initiative, aims to treat various cancers associated with HPV types 16 and 18. The study will include a unique cohort for HIV-positive patients with HPV-associated cancers. The trial's opening will trigger a milestone payment from MedImmune to Inovio.
Read more →INOInovio, DNA 암호화 단일클론 항체(dMAb™) 플랫폼의 효능 입증하는 임상전 논문 3건과 2019년 첫 임상시험 계획 발표
Inovio Pharmaceuticals has reported significant advancements in its DNA medicine platform, particularly with its dMAb™ technology. The company is focusing on clinical trials for various applications, including treatments related to PCSK9. The positive outcomes from these trials indicate a strong potential for future developments in the field of DNA-based therapeutics.
Read more →INOイノビオ社、3件の前臨床試験で同社のDNAコード化モノクローナル抗体 (dMAb™) プラットフォームの効力をさらに実証し、2019年初旬の初回臨床試験に向けて準備を進める
Inovio Pharmaceuticals (INO) has announced advancements in its DNA-based monoclonal antibody technology (dMAb™). The company is preparing for a Phase 1 trial focused on treating cardiovascular diseases and other conditions. This trial aims to leverage promising data from previous studies and is backed by significant external funding. The dMAb technology is expected to provide innovative solutions for various diseases.
Read more →INOInovio在三項臨床前試驗結果文獻中進一步顯示Inovio的DNA編碼單克隆抗體（dMAb™）平台的療效，並準備在2019年初進行首次臨床試驗
Inovio Pharmaceuticals has announced positive results from its preclinical trials of its DNA monoclonal antibody (dMAb) technology. The trials demonstrated significant efficacy against various diseases, including heart disease and infectious diseases. Inovio is preparing to advance its dMAb products into clinical trials, with substantial funding secured to support this development. The company aims to leverage its innovative technology to address unmet medical needs.
Read more →INOInovio Further Demonstrates Potency of its DNA-Encoded Monoclonal Antibody (dMAb™) Platform in Three Preclinical Publications and Prepares for First Clinical Trial in Early 2019
Inovio Pharmaceuticals announced promising results from three preclinical studies of its DNA-Encoded monoclonal antibody (dMAb) technology, which showed effectiveness against cardiovascular disease, Ebola, and Lyme disease. The company plans to initiate its first clinical trial for an infectious disease treatment dMAb product in early 2019, backed by substantial funding. These findings highlight the potential of dMAb as a cost-effective and efficient alternative to traditional monoclonal antibodies.
Read more →INOInovio Prepares for Growth & Commercialization With Leadership Appointments
Inovio Pharmaceuticals has announced key leadership appointments to bolster its commercialization efforts for its DNA-based immunotherapies and vaccines. Notable appointments include Professor Rafi Ahmed to the Scientific Advisory Board and Mark Twyman as Vice President of Commercial. These changes aim to enhance Inovio's capabilities in developing treatments for cancer and infectious diseases.
Read more →INOInovio Pharmaceuticals Reports 2018 Third Quarter Financial Results
Inovio Pharmaceuticals reported its third quarter financial results for 2018, highlighting advancements in clinical trials, including the Phase 3 REVEAL 1 study and various immuno-oncology trials. Despite a decrease in revenue compared to the previous year, the company noted significant progress in its vaccine programs and collaborations. The management will discuss these results in a conference call today.
Read more →INOInovio Pharmaceuticals to Participate in Upcoming Investment Conferences
Inovio Pharmaceuticals announced its participation in several upcoming investment conferences, including the Stifel 2018 Healthcare Conference and the Piper Jaffray 30th Annual Healthcare Conference. The company's President and CEO, Dr. J. Joseph Kim, will present at these events. Inovio is recognized for its development of DNA immunotherapies targeting cancer and infectious diseases.
Read more →INOInovio HIV Vaccine PENNVAX -GP Delivered Intradermally Generated Robust, Long-Term Best-In-Class Antibody and T Cell Immune Responses
PLYMOUTH MEETING, Pa., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its synthetic HIV vaccine PENNVAX®-GP delivered via intradermal route demonstrated durable and robust antibody and T cell immune responses measured throughout t
Read more →INOInovio Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 8, 2018
PLYMOUTH MEETING, Pa., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it will host a conference call and live webcast to report its 2018 third quarter financial results on Thursday, November 8, 2018 at 4:30 p.m. ET. A live and a
Read more →INOInovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150
Study Results Presented at a Major European Cancer Conference (ESMO) PLYMOUTH MEETING, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that new data from the company’s recently completed Phase 1b study with INO-5150 demonstrated a
Read more →INOInovio’s DNA-Encoded Monoclonal Antibody (dMAb™) Platform Moves Ahead with Positive Data, Patents and Grants
Two new U.S. Patents for Inovio’s dMAb technology were issued Inovio awarded new $2.2 million Gates Foundation grant to support dMAb development and next-generation dMAb delivery clinical device PLYMOUTH MEETING, Pa., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, In
Read more →INOInovio’s Ebola Vaccine Provides 100% Protection And Elicits Long-Lasting Immune Responses in Preclinical Studies
Article in Journal of Infectious Diseases Supports Rationale For Inovio’s Ebola Vaccine Stockpile Program PLYMOUTH MEETING, Pa., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its Ebola vaccine (INO-4212) provided 100% protectio
Read more →INOInovio Successfully Develops First DNA-Encoded Monoclonal Antibody (dMAb™) Checkpoint Inhibitor and Demonstrates Tumor Shrinkage in Preclinical Studies
PLYMOUTH MEETING, Pa., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today the successful animal testing of DNA-encoded monoclonal antibodies targeting the immune checkpoint molecule CTLA-4 as published in Cancer Research. The breakthrough
Read more →INOInovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges
H3N2 virus has been one of the most deadly flu strains in the past 50 years; And is always matched with the least effective seasonal influenza vaccine Preclinical work is supported by an NIH grant PLYMOUTH MEETING, Pa., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals
Read more →INOInovio Doses 1st Subject in Phase 1/2 Clinical Trial For Vaccine Against Deadly MERS Infection
PLYMOUTH MEETING, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today announced the dosing of the first subject with its vaccine to prevent infection from the deadly MERS virus (Middle East Respiratory Syndrome) in a Phase 1/2a study
Read more →INOInovio and Korean Partner Dose 1st Subject In Trial to Develop World’s First Vaccine to Prevent Hepatitis C Infection
PLYMOUTH MEETING, Pa., and SEOUL, Korea, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and GeneOne Life Science (KSE: 011000) today announced they have dosed the first patient in a Phase 1 study designed to evaluate a preventive vaccine against hepa
Read more →INOInovio Treats First Patient in Immuno-Oncology Study for Advanced or Metastatic Bladder Cancer in Combination with Roche/Genentech’s Atezolizumab
PLYMOUTH MEETING, Pa., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has dosed its first patient in a Phase 1/2a study designed to evaluate the safety, immunogenicity and clinical efficacy of INO-5401, Inovio’s novel cancer im
Read more →INOInovio Announces First Patient Dosed in Trial to Determine PENNVAX -GP’s Ability to Induce Remission of HIV Infection
PLYMOUTH MEETING, Pa., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the first participant has been dosed with PENNVAX®-GP in a randomized clinical trial that will evaluate its ability to drive remission of HIV infection. This va
Read more →INOInovio Pharmaceuticals Reports 2018 Second Quarter Financial Results
PLYMOUTH MEETING, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a late-stage biotechnology company focused on the development and commercialization of DNA immunotherapies targeted against cancers and infectious diseases, today reported financia
Read more →INOInovio Partners with AIDS Malignancy Consortium to Advance Inovio’s HPV Therapy for High-Grade Anal Dysplasia in HIV-positive Patients
PLYMOUTH MEETING, Pa., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has entered into a partnership with the AIDS Malignancy Consortium (AMC) to evaluate VGX-3100, Inovio’s immunotherapy for treating HPV-associated precancerou
Read more →INOInovio Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 7, 2018
PLYMOUTH MEETING, Pa., July 24, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2018 second quarter financial results on Tuesday, August 7, 2018 at 4:30 p.m. ET. A live and arch
Read more →INOInovio’s MERS Vaccine Generates High Levels of Antibodies and Induces Broad-based T Cell Responses in Phase 1 Study
PLYMOUTH MEETING, Pa., June 27, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced positive Phase 1 results of its collaborative vaccine study with INO-4700 (GLS-5300) against MERS (Middle East Respiratory Syndrome). Results for INO-4700, which is
Read more →INOInovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron’s PD-1 Inhibitor
PLYMOUTH MEETING, Pa., June 21, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has dosed its first patient as part of its Phase 1/2 immuno-oncology trial in patients with newly diagnosed glioblastoma (GBM). The efficacy trial is designe
Read more →INOInovio CEO to Speak on Viral Epidemic Preparedness Panel at BIO International Convention
PLYMOUTH MEETING, Pa., May 31, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President and CEO, will address Inovio’s ability to respond to emerging viral threats at the Biotechnology Industry Organization’s annual inte
Read more →INOInovio Boosts Leadership Focused on Partnership and Grant Funding By Appointing Two New VPs for Business Development and R&D
PLYMOUTH MEETING, Pa., May 24, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has bolstered its efforts to attract partnerships and collaborations and increase non-dilutive funding with the hiring of an accomplished business development
Read more →INOInovio Opens Phase 2 Trial for VGX-3100 in Third Indication To Treat HPV – The No. 1 Sexually Transmitted Disease
PLYMOUTH MEETING, Pa., May 21, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has commenced a Phase 2 clinical trial to evaluate the efficacy of VGX-3100 in adult men and women with human papilloma virus (HPV)-related anal dysplasia. Re
Read more →INOInovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer
PLYMOUTH MEETING, Pa., May 17, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced a poster presentation of additional prostate cancer data (Abstract #229675) at the American Society of Clinical Oncology (ASCO) annual meeting to be held in Chicago,
Read more →INOInovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses Measured One Year After The Start of Clinical Trial
PLYMOUTH MEETING, Pa., May 15, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its HIV vaccine, PENNVAX®-GP, maintained durable and robust immune responses at month 12, a full six months after the last dose in a Phase 1 clinical study. Ino
Read more →INOInovio Pharmaceuticals Reports 2018 First Quarter Financial Results
PLYMOUTH MEETING, Pa., May 09, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA immunotherapies targeted against cancers and infectious diseases, today report
Read more →INOInovio Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018
PLYMOUTH MEETING, Pa., April 30, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2018 first quarter financial results on Wednesday, May 9, 2018 at 4:30 p.m. ET. A live and archi
Read more →INOInovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
PLYMOUTH MEETING, Pa. and OSLO, Norway, April 11, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and CEPI – the Coalition for Epidemic Preparedness Innovations – today announced a partnership under which Inovio will develop vaccine candidates against Lassa fev
Read more →INOInovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS Major investment by Coalition for Epidemic Preparedness Innovations (CEPI) to advance vac
Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS Major investment by Coalition for Epidemic Preparedness Innovations (CEPI) to advance vaccine development and manufacturing on two of CEPI s highest priority infectious diseases PL
Read more →INOInovio Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences Conference
PLYMOUTH MEETING, Pa., April 02, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, Inovio’s President & CEO, will provide a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference, being held April
Read more →INOInovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
PLYMOUTH MEETING, Pa., March 20, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced it has closed an agreement providing ApolloBio Corp. (NEEQ:430187) with the exclusive right to develop, manufacture and commercialize VGX-3100, Inovio’s DNA immunot
Read more →INOInovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results
PLYMOUTH MEETING, Pa., March 14, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the fourth quarter and year ended December 31, 2017. Total revenue was $8.8 million and $42.2 million for the quarter and year ended December
Read more →INOInovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection
PLYMOUTH MEETING, Pa., March 14, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that interim Phase 1 results show its DNA immunotherapy designed to treat hepatitis B virus (HBV) infection was safe, well-tolerated and generated virus-specific T
Read more →INOInovio Pharmaceuticals to Report Fourth Quarter and Year End 2017 Financial Results on March 14, 2018
PLYMOUTH MEETING, Pa., March 12, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 fourth quarter and year end financial results on Wednesday, March 14, 2018 at 4:30 p.m. ET.
Read more →INOInovio and The Wistar Institute Receive More Than $4.6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria
PLYMOUTH MEETING, Pa., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the company is collaborating with The Wistar Institute to advance two novel SynCon® vaccine programs against tuberculosis (TB) and malaria, fully funded by more
Read more →INOInovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1 Influenza Viruses From the Last 100 Years in Animal Models
PLYMOUTH MEETING, Pa., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Inovio’s synthetic vaccine approach using a collection of synthetic DNA antigens generated broad protective antibody responses against all major deadly strains
Read more →INOInovio’s Co-Founder along with its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents for 2016
PLYMOUTH MEETING, Pa., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. David B. Weiner, its co-founder; and Dr. Jian Yan, the company’s Lead Antigen Designer, have been selected as two of the “Top 20 Translational Researchers”
Read more →INOInovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations
Advances development of Inovio’s ASPIRE™ (Antigen SPecific Immune REsponses) immunotherapy platform as a foundation for novel combination regimen approaches Engages the Parker Institute’s extensive immunotherapy expertise and academic and research network on studies that have th
Read more →INOImmediate Release CONTACTS: Investors: Ben Matone, Inovio, 484-362-0076, ben.matone@inovio.com Media: Jeff Richardson, Inovio, 267-440-4211, jrichardson@inovio.com Inovio Receives Milestone Payment from MedI
Investors: Ben Matone, Inovio, 484-362-0076, ben.matone@inovio.com Media: Jeff Richardson, Inovio, 267-440-4211, jrichardson@inovio.com Inovio Receives Milestone Payment from MedImmune As MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cance
Read more →INOInovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2
PLYMOUTH MEETING, Pa., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has received a milestone payment from MedImmune as MEDI0457 (formerly called INO-3112 which MedImmune in-licensed from Inovio) in combination with durvalumab (MED
Read more →INOImmediate Release CONTACTS: Investors: Ben Matone, Inovio, 484-362-0076, ben.matone@inovio.com Media: Jeff Richardson, Inovio, 267-440-4211, jrichardson@inovio.com Inovio Enters License and Collaboration Agr
Investors: Ben Matone, Inovio, 484-362-0076, ben.matone@inovio.com Media: Jeff Richardson, Inovio, 267-440-4211, jrichardson@inovio.com Inovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China Inovio to receive $
Read more →INOInovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
PLYMOUTH MEETING, Pa., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it entered an amended agreement providing ApolloBio Corporation (NEEQ:430187) with the exclusive right to develop and commercialize VGX-3100, Inovio’s DNA immun
Read more →INOInovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development
PLYMOUTH MEETING, Pa., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has promoted Dr. Laurent Humeau to Senior Vice President, Research & Development, reporting to Dr. J. Joseph Kim, Inovio’s President & CEO. Dr. Humeau joined Inovio in 2014 as Vice
Read more →INOInovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors
PLYMOUTH MEETING, Pa., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Wendy Yarno has been elected to the company's Board of Directors. Wendy Yarno has over 25 years of experience in the pharmaceutical industry highlighted by her
Read more →INOImmediate Release CONTACTS: Investors/Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors Former Chief M
Investors/Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors Former Chief Marketing Officer at Merck Also Brings Women s Health Management Expertise PLYMOUTH MEETING, Pa.
Read more →INOInovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clinical Efficacy
PLYMOUTH MEETING, Pa., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that post-hoc analysis of data generated from its phase 2b trial of VGX-3100 identified immune correlates and biomarker signatures predictive of treatment success.
Read more →INOInovio Pharmaceuticals SynCon TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor and Improves Survival in Preclinical Tumor Model
PLYMOUTH MEETING, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) demonstrated the synergistic effect of combining Inovio’s TERT (telomerase reverse transcriptase) cancer immunotherapy in combination with a checkpoint inhibitor in preclinical tumo
Read more →INOInovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference
PLYMOUTH MEETING, Pa., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that two of its cancer immunotherapies demonstrated antigen-specific T-cell stimulation in phase 1 studies. INO-3112 (now called MEDI0457), an investigational T-cell
Read more →INOInovio Pharmaceuticals to Participate In Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences: Stifel 2017 Healthcare Conference Presentation and 1x1 meetings Dr. Niranjan Y
Read more →INOInovio Pharmaceuticals Reports 2017 Third Quarter Financial Results
PLYMOUTH MEETING, Pa., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended September 30, 2017. Total revenue was $2.6 million for the three months ended September 30, 2017, compared to $12.5 million f
Read more →INOInovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhibitor
PLYMOUTH MEETING, Pa., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today initiated a phase 1b/2a immuno-oncology trial in patients with newly diagnosed glioblastoma (GBM) designed to evaluate cemiplimab (also known as REGN2810), a PD-1 inhibitor de
Read more →INOInovio Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 8, 2017
PLYMOUTH MEETING, Pa., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 third quarter financial results on Wednesday, November 8, 2017 at 4:30 p.m. ET. A live and a
Read more →INOInovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study
PLYMOUTH MEETING, Pa., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced results of a study in which a DNA vaccine provided 100% protection for non-human primates challenged with a lethal dose of the Lassa fever virus. Lassa is a virulent
Read more →INOInovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 Checkpoint Inhibitor in Advanced Bladder Cancer
PLYMOUTH MEETING, Pa., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced initiation of a phase 1b/2 immuno-oncology trial to evaluate Genentech/Roche’s atezolizumab (TECENTRIQ®) in combination with Inovio’s INO-5401, a T cell activating i
Read more →INOInovio’s Positive Zika Vaccine Clinical Study Data Published in New England Journal of Medicine
PLYMOUTH MEETING, Pa., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) reported today on positive safety and immune response results from a first-in-man, multi-center phase 1 trial of a vaccine against the Zika virus. The phase 1 trial of Inovio’s DNA
Read more →INOInovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies
PLYMOUTH MEETING, Pa., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the development of its DNA-based monoclonal antibody program received a boost from two peer-reviewed scientific papers that demonstrate their impact on prostat
Read more →INOInovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection
PLYMOUTH MEETING, Pa., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Korean Ministry of Food and Drug Safety approved the initiation of a study to evaluate GLS-5300, Inovio’s vaccine against the MERS virus (Middle East Respi
Read more →INOInovio’s Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer
PLYMOUTH MEETING, Pa., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced that an interim data analysis showed that its INO-5150 cancer immunotherapy product generated antigen-specific CD8+ killer T cell responses measured in peripheral
Read more →INOInovio Pharmaceuticals Reports 2017 Second Quarter Financial Results
PLYMOUTH MEETING, Pa., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended June 30, 2017. Total revenue was $20.4 million for the three months ended June 30, 2017, compared to $6.2 million for the sam
Read more →INOInovio Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017
PLYMOUTH MEETING, Pa., July 26, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 second quarter financial results on Tuesday, August 8, 2017 at 4:30 p.m. ET. A live and arch
Read more →INOInovio Announces Pricing of Public Offering of Common Stock
PLYMOUTH MEETING, Pa., July 19, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock, offered at a price to the public of $6.00 per share. The gross proceeds to
Read more →INOInovio Announces Proposed Public Offering of Common Stock
Inovio Announces Proposed Public Offering of Common Stock PLYMOUTH MEETING, Pa., July 18, 2017 (Globe Newswire) Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that it intends to offer and sell $75.0 million of shares of its common stock in an underwritten public off
Read more →INOInovio’s DNA-based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation
PLYMOUTH MEETING, Pa., July 06, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based monoclonal antibody product for flu produced broadly cross-reactive antibodies that provided complete protection from a lethal challenge with multiple
Read more →INOInovio Announces Leadership Appointments
PLYMOUTH MEETING, Pa., June 28, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced leadership appointments to support its growth and expanding strategic and operational initiatives. Inovio promoted Dr. Keiko Simon to Vice President, Alliance and Pr
Read more →INOInovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention
PLYMOUTH MEETING, Pa., June 19, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President & CEO, will participate on a panel, titled “Platform Technologies: The Key to Responding to Emerging Infectious Diseases,” at the 2
Read more →INOInovio Fully Enrolls 160 Subjects in Puerto Rico for Second Zika Vaccine Phase 1 Trial; Continues Leadership to Advance an Effective Preventive Solution
PLYMOUTH MEETING, Pa., June 15, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has completed enrollment of its phase 1 clinical trial in Puerto Rico evaluating its Zika vaccine, GLS-5700. Inovio is developing this vaccine with GeneOne L
Read more →INOImmediate Release CONTACTS: Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com Inovio Begi
Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer FDA removes clinical hold on phase 3; Inovio to immediately begin recruiting subjects PLYMOUTH MEETING, Pa. June 8, 2017 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced t
Read more →INOInovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer
PLYMOUTH MEETING, Pa., June 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has commenced its phase 3 clinical program to evaluate the efficacy of Inovio’s DNA-based immunotherapy, VGX-3100, to treat cervical dysplasia caused by huma
Read more →INOInovio Zika Vaccine Prevents Persistence of Virus and Damage in Male Reproductive Tract in Pre-Clinical Study
PLYMOUTH MEETING, Pa., June 07, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based Zika vaccine (GLS-5700) protected against Zika virus-induced damage to testes and sperm, and prevented persistence of the virus in the reproductive tra
Read more →INOInovio Announces Clinical Trial Collaboration to Evaluate a Novel T-cell Immunotherapy in Combination with a PD-L1 Checkpoint Inhibitor
PLYMOUTH MEETING, Pa., June 01, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced a clinical collaboration with Genentech, a member of the Roche Group, for advanced bladder cancer. The phase 1b/2 immuno-oncology trial will evaluate Genentech’s ate
Read more →INOInovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study
PLYMOUTH MEETING, Pa., May 24, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by a
Read more →INOInovio Pharmaceuticals Reports 2017 First Quarter Financial Results
PLYMOUTH MEETING, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended March 31, 2017. Total revenue was $10.4 million for the three months ended March 31, 2017, compared to $8.1 million for the sa
Read more →INOInovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer
PLYMOUTH MEETING, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced MedImmune, AstraZeneca’s global biologics research and development arm, will start a new clinical trial investigating the combination of MEDI0457, an immunotherapy de
Read more →INOInovio & Regeneron Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
PLYMOUTH MEETING, Pa. and TARRYTOWN, N.Y., May 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced a clinical study agreement for a phase 1b/2a immuno-oncology trial. The study will be conducted
Read more →INOInovio Pharmaceuticals to Participate in Bank of America Merrill Lynch 2017 Healthcare Conference
PLYMOUTH MEETING, Pa., May 02, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will participate in the Bank of America Merrill Lynch 2017 Healthcare Conference May 16-18th, 2017 in Las Vegas, NV. Dr. J. Joseph Kim, President and CEO of I
Read more →INOInovio Pharmaceuticals to Report First Quarter 2017 Financial Results May 10, 2017
PLYMOUTH MEETING, Pa., April 26, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 first quarter financial results on Wednesday, May 10, 2017 at 4:30 p.m. ET. A live and arch
Read more →INOInovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers
New study expands VGX-3100 program for evaluating therapeutic applications in HPV-related pre-cancers with high medical need VGX-3100 previously demonstrated efficacy in regressing HPV-related cervical pre-cancer PLYMOUTH MEETING, Pa., April 24, 2017 (GLOBE NEWSWIRE) -- Inovio
Read more →INOInovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Expanded Clinical Trial
PLYMOUTH MEETING, Pa., April 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today preliminary results from the expanded stage of its phase I study, EBOV-001. The expanded study examined different regimens of its Ebola DNA vaccine INO-4201 using i
Read more →INOInovio and Collaborators Receive NIH Grant to Evaluate HIV Immunotherapy PENNVAX -GP’s Ability to Induce Remission of HIV Infection and End Lifetime of Drug Therapy
PLYMOUTH MEETING, Pa., March 30, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its academic and industry collaborators received a multi-year $6.95 million grant from the NIH’s National Institute of Allergy and Infectious Diseases to devel
Read more →INOImmediate Release CONTACTS: Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com George Bick
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com George Bickerstaff Elected to Inovio s Board of Directors Former Novartis CFO brings finance, fundraising an
Read more →INOInovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results
PLYMOUTH MEETING, Pa., March 15, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the fourth quarter and year ended December 31, 2016. Total revenue was $8.5 million and $35.4 million for the quarter and year ended December
Read more →INOInovio Pharmaceuticals to Report Fourth Quarter and Year End 2016 Financial Results on March 15, 2017
PLYMOUTH MEETING, Pa., March 09, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to discuss its 2016 fourth quarter and year end financial results and provide a corporate update on Wednesday,
Read more →INOInovio’s SynCon WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy
PLYMOUTH MEETING, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its SynCon® WT1 cancer immunotherapy was capable of breaking immune tolerance and inducing neo-antigen-like T cell responses to cause tumor regression in pre-cl
Read more →INOInovio Reports New Positive Clinical Data on Vaccine Advances in the Fight Against Emerging Infectious Diseases
Significant immune responses observed in 100% of Zika-vaccinated subjects and 98% of MERS-vaccinated human subjects in separate phase I studies Data reported at Coalition for Epidemic Preparedness Innovation (CEPI) meeting PLYMOUTH MEETING, Pa., Feb. 23, 2017 (GLOBE NEWSWIRE) -
Read more →INOImmediate Release CONTACTS: Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com Inovio and
CONTACTS: Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com Inovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer Immun
Read more →INOInovio and ApolloBio to Collaborate on Development and Commercialization of HPV Pre-cancer Immunotherapy VGX-3100 in Greater China
PLYMOUTH MEETING, Pa., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has entered into a collaboration and license agreement providing ApolloBio Corporation (NEEQ:430187) with the exclusive right to develop and commercialize VG
Read more →INOInovio’s Zika Vaccine Generates Robust Immune Responses in First Human Study
PLYMOUTH MEETING, Pa., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based Zika vaccine (GLS-5700) generated robust antigen-specific antibody responses in a first-in-man, multi-center phase I trial. In initial testing, Zika-na
Read more →INOInovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute
PLYMOUTH MEETING, Pa., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the International Vaccine Institute (IVI) will provide new funding and support to further advance GLS-5300, Inovio’s vaccine to prevent Middle East Respiratory
Read more →INOInovio Pharmaceuticals Awarded $6.1 Million Sub-grant Through Wistar Institute to Develop DNA-based Monoclonal Antibodies Against Zika Virus
Grant Provides Funding to Help Prepare New Zika Therapy for Human Trials Inovio Already in Two Human Trials for its Preventive Zika Vaccine PLYMOUTH MEETING, Pa. & PHILADELPHIA, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it
Read more →INOInovio Applies to Cease Reporting to Canadian Securities Regulatory Authorities; NASDAQ Listing and US Reporting Unaffected
PLYMOUTH MEETING, Pa., Nov. 25, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that further to the voluntary delisting of Genetronics Biomedical Corporation, a predecessor of the Company, from the Toronto Stock Exchange on January 17, 2003, it
Read more →INOInovio’s Co-Founder and Chair of its Scientific Advisory Board Selected as a Top 20 Translational Researcher
PLYMOUTH MEETING, Pa., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. David B. Weiner, its co-founder, board member and chair of its scientific advisory board, has been selected as a “Top 20 Translational Researcher” for the y
Read more →INOInovio Wins Deloitte’s “Fast 500” Growth Award
PLYMOUTH MEETING, Pa., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced it ranked No. 107 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech comp
Read more →INOInovio’s Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer
PLYMOUTH MEETING, Pa., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced an interim data analysis showing that its INO-3112 cancer immunotherapy product generated antigen-specific CD8+ killer T cell responses measured both in tumor tissu
Read more →INOInovio Pharmaceuticals Zika Vaccine Protects Animals from Infection, Brain Damage and Death
Article published in npj Vaccines demonstrates that DNA vaccine protected 100% of animals from Zika infection after exposure to the virus PLYMOUTH MEETING, Pa., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Inovio and its collab
Read more →INOInovio Pharmaceuticals Reports 2016 Third Quarter Financial Results
PLYMOUTH MEETING, Pa., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended September 30, 2016. The following financial results provide a year-over-year comparison of the third quarter in 2016 and 2015.
Read more →INOInovio Pharmaceuticals to Report Third Quarter 2016 Financial Results November 9, 2016
PLYMOUTH MEETING, Pa., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to discuss its 2016 third quarter financial results and provide a corporate update on Wednesday, November 9, 201
Read more →INOImmediate Release CONTACTS: Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com Inovio Anno
CONTACTS: Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation De
Read more →INOInovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed
PLYMOUTH MEETING, Pa., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its proposed phase III clinical program for VGX-3100. A clinical hold is a notificatio
Read more →INOInovio CEO Selected As 2016 Healthcare Innovator
PLYMOUTH MEETING, Pa., Oct. 21, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced that its President and Chief Executive Officer, Dr. J. Joseph Kim, has been selected as a 2016 Healthcare Innovator by a panel of scientific and medical experts con
Read more →INOInovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio
PLYMOUTH MEETING, Pa., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced strategic leadership appointments to support the advancement of its portfolio of DNA-based cancer immunotherapies and infectious disease vaccines. Inovio has an exte
Read more →INOInovio’s Zika Vaccine Selected As 2016 Technology Breakthrough
PLYMOUTH MEETING, Pa., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its Zika vaccine in development has been named a 2016 Technology Breakthrough by the editors of Popular Mechanics magazine, the leading technology voice in the
Read more →INOInovio Pharmaceuticals to Present at Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will present a corporate overview at the following upcoming conferences: Citi 11th Annual Biotech Conference Mandarin Oriental, Boston, Thursday,
Read more →INOInovio Launches Zika Vaccine Trial in Midst of Puerto Rico Epidemic to Explore Early Signals of Vaccine Efficacy
PLYMOUTH MEETING, Pa., Aug. 29, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced it has initiated a clinical study of its preventive Zika vaccine (GLS-5700) in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public
Read more →INOInovio Licenses Veterinary Foot and Mouth Disease Vaccine to Plumbline Life Sciences
PLYMOUTH MEETING, Pa., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced it has licensed a veterinary vaccine for foot and mouth disease (FMD) to Plumbline Life Sciences (KONEX: 222670), an animal health company headquartered in South Kor
Read more →INOInovio Pharmaceuticals Expands Positive Phase I Ebola Vaccine Trial to Identify Most Optimal Immunization Regimen
PLYMOUTH MEETING, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the company is more than doubling study enrollment to further characterize and identify in humans the most optimal immunization regimen using intradermal (skin)
Read more →INOInovio Pharmaceuticals Reports 2016 Second Quarter Financial Results
PLYMOUTH MEETING, Pa., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended June 30, 2016. The following financial results provide a year-over-year comparison of the second quarter in 2016 and 2015. Tot
Read more →INOInovio Pharmaceuticals Appoints Dr. Ami Shah Brown As Vice President Regulatory Affairs
PLYMOUTH MEETING, Pa., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the appointment of Dr. Ami Shah Brown as Vice President Regulatory Affairs. Dr. Brown, who joined Inovio in 2011 as Senior Director of Regulatory Affairs, will be re
Read more →INOInovio will Independently Develop Hepatitis B Immunotherapy
PLYMOUTH MEETING, Pa., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the company will continue to develop its hepatitis B DNA immunotherapy (INO-1800) independently following Roche’s notice that it will discontinue its collaboration w
Read more →INOImmediate Release CONTACTS: Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com Inovio will
CONTACTS: Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com Inovio will Independently Develop Hepatitis B Immunotherapy PLYMOUTH MEETING, PA August 3, 2016
Read more →INOInovio Pharmaceuticals Doses First Subject in Zika Vaccine Clinical Trial
PLYMOUTH MEETING, Pa., July 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the dosing of the first subject in its multi-center phase I trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700). In addition to the previously announced US FDA ap
Read more →INOInovio Pharmaceuticals to Report Second Quarter 2016 Financial Results August 8, 2016
PLYMOUTH MEETING, Pa., July 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to discuss its 2016 second quarter financial results and provide a corporate update on Monday, August 8, 2016 at
Read more →INOInovio Deploys DNA-based Monoclonal Antibody Technology in Quest to Cure HIV
PLYMOUTH MEETING, Pa., July 14, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its novel DNA-based monoclonal antibody technology will be deployed to develop products which could be used alone and in combination with other immunotherapies
Read more →INOInovio Pharmaceuticals and GeneOne Life Science Receive Approval for First-in-Man Zika Vaccine Clinical Trial
PLYMOUTH MEETING, Pa. and SEOUL, South Korea, June 20, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and GeneOne Life Science, Inc. (KSE:011000) today announced that they have received approval to initiate a phase I human trial to evaluate Inovio’s Zika DNA v
Read more →INOInovio Pharmaceuticals Zika Vaccine Produces Robust Immune Responses in Non-Human Primates
PLYMOUTH MEETING, Pa., May 16, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that testing of its synthetic vaccine for the Zika virus induced robust antibody and T cell responses in non-human primates (monkeys), demonstrating the product’s pot
Read more →INOInovio Pharmaceuticals to Present at UBS Global Healthcare Conference
PLYMOUTH MEETING, Pa., May 11, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported that the Company will present a corporate overview at the UBS Global Healthcare Conference on Wednesday, May 25th at 8:30AM EDT. A live and archived version of presen
Read more →INOInovio Pharmaceuticals Reports 2016 First Quarter Financial Results
PLYMOUTH MEETING, Pa., May 09, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended March 31, 2016. Total revenue was $8.1 million for the three months ended March 31, 2016, compared to $5.2 million for the sam
Read more →INOInovio Pharmaceuticals Showcases its Broad Pipeline of DNA-based Immunotherapies, Vaccines and dMAbs at the American Society of Gene & Cell Therapy
PLYMOUTH MEETING, Pa., May 04, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it will exhibit the breadth and promise of its cancer and infectious disease immunotherapy, vaccine and DNA-based monoclonal antibody (dMAb) pipeline in 10 presentati
Read more →INOInovio Pharmaceuticals Completes Acquisition of Needle-Free Injection Technology
PLYMOUTH MEETING, Pa., May 02, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has closed the transaction to acquire all of BioJect Medical Technologies Inc.’s assets, including pioneering needle-free jet injection technology, devices, and in
Read more →INOInovio Partners with National Cancer Institute and Mayo Clinic to Initiate Hepatitis C Immunotherapy Clinical Trial
PLYMOUTH MEETING, Pa., April 27, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today its immunotherapy for hepatitis C (INO-8000) will be evaluated in a phase I trial in chronically infected patients who are not receiving other hepatitis C virus (HC
Read more →INOInovio Pharmaceuticals to Report First Quarter 2016 Financial Results May 9, 2016
PLYMOUTH MEETING, Pa., April 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2016 first quarter financial results on Monday, May 9, 2016 at 8:30 a.m. ET. A live and archived
Read more →INOInovio Ebola Vaccine Generates Robust Immune Responses in Humans
PLYMOUTH MEETING, Pa., March 30, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its Ebola vaccine, INO-4212, was safe, tolerable, and generated strong T cell and antibody responses in its fully enrolled phase I study of 75 healthy subjects
Read more →INOInovio Pharmaceuticals HPV Immunotherapy Selected as “Best Therapeutic Vaccine” by World Vaccine Congress
PLYMOUTH MEETING, Pa., March 30, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its immunotherapy to treat cervical dysplasia (VGX-3100) was recognized as "Best Therapeutic Vaccine" by the World Vaccine Congress held this week in Washingto
Read more →INOInovio Updates INO-3112 HPV Immunotherapy Development Plan
PLYMOUTH MEETING, Pa., March 29, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced a clinical strategy update to take its INO-3112 HPV immunotherapy into human studies in combination with selected immunotherapy molecules from MedImmune, the global
Read more →INOInovio’s DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge in Preclinical Study
PLYMOUTH MEETING, Pa., March 22, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its novel dMAb antibody and DNA vaccine targeting the chikungunya virus (CHIKV) provided 100% protection against a lethal virus challenge in mice. This breakth
Read more →INOInovio Signs Collaborative Research Agreements With Wistar Institute for DNA-based Immunotherapies and Vaccines
New Agreement Follows Dr. David B. Weiner’s Move to Wistar from the University of Pennsylvania (UPenn) Inovio will maintain all existing license agreements with UPenn PLYMOUTH MEETING, Pa., March 16, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced t
Read more →INOInovio Pharmaceuticals Reports 2015 Fourth Quarter and Year End Financial Results
PLYMOUTH MEETING, Pa., March 14, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the fourth quarter and year ended December 31, 2015. Total revenue was $5.9 million and $40.6 million for the quarter and year ended December
Read more →INOInovio Pharmaceuticals Acquires Needle-Free Injection Technology to Advance Strategy for Next-Generation Vaccines
PLYMOUTH MEETING, Pa., March 14, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has signed a definitive agreement to acquire all of Bioject Medical Technologies Inc.’s assets including pioneering needle-free jet injection technology, devices
Read more →INOInovio Pharmaceuticals Appoints DNA Immunotherapy Pioneer David B. Weiner, Ph.D., to its Board of Directors
PLYMOUTH MEETING, Pa., March 11, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that David B. Weiner, Ph.D., recognized in scientific circles as the “father of DNA vaccines and immunotherapies,” has been appointed to Inovio’s Board of Directors
Read more →INOImmediate Release CONTACTS: Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com Inovio Phar
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com Inovio Pharmaceuticals Appoints DNA Immunotherapy Pioneer David B. Weiner, Ph.D., to its Board of Directors
Read more →INOInovio Pharmaceuticals to Report Fourth Quarter and Year End 2015 Financial Results on March 14, 2016
PLYMOUTH MEETING, Pa., March 03, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2015 fourth quarter and year-end financial results on Monday, March 14, 2016 at 8:30 a.m. ET. A
Read more →INOInovio Pharmaceutical's DNA Vaccine for Zika Virus Induces Robust Immune Responses in Preclinical Study
Biotech begins clinical manufacturing; expects to test Zika vaccine in humans in 2016 PLYMOUTH MEETING, Pa., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that preclinical testing of its synthetic vaccine for the Zika virus induced r
Read more →INOInovio Pharmaceuticals to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that management will participate at three upcoming investor conferences in February: BIO CEO & Investor Conference RBC Capital Markets Global Healthcare Conference
Read more →INOInovio Pharmaceuticals and GeneOne Life Science Initiate Patient Recruitment for MERS Vaccine Trial
PLYMOUTH MEETING, Pa., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the beginning of recruitment for its collaborative vaccine study for MERS (Middle East Respiratory Syndrome). Inovio and GeneOne Life Science Inc. (KSE:011000) are c
Read more →INOInovio Pharmaceuticals Awarded Grant to Advance Needle-Free Vaccine Delivery Device
PLYMOUTH MEETING, Pa., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has been selected to receive a $500,000 grant from the U.S. Army’s Small Business Innovation Research (SBIR) program to further advance the development of Inovio’
Read more →INOInovio Pharmaceuticals to Present at Biotech Showcase
PLYMOUTH MEETING, Pa., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President and CEO, will give a corporate presentation on Tuesday, January 12th at 9:30AM PST at Biotech Showcase 2016. Dr. Kim will also part
Read more →INOInovio Pharmaceuticals Adds Dr. Prakash Bhuyan to VGX-3100 Leadership Team for HPV-Related Dysplasia
PLYMOUTH MEETING, Pa., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has appointed Prakash Bhuyan, M.D, Ph.D., as Vice President, Clinical Development. Dr. Bhuyan will lead the clinical development of Inovio’s programs to treat HPV
Read more →INOInovio Pharmaceuticals to Present at Piper Jaffray Healthcare Conference
PLYMOUTH MEETING, Pa., Nov. 23, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported that Dr. J. Joseph Kim, President and CEO, will participate in the Piper Jaffray 27th Annual Healthcare Conference on Wednesday, December 2nd at 3:30PM ET. A live an
Read more →INOInovio Pharmaceuticals Reports 2015 Third Quarter Results
PLYMOUTH MEETING, Pa., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended September 30, 2015. Total revenue was $24.2 million and $34.6 million for the three and nine months ended September 30, 2015,
Read more →INOInovio’s INO-3112 Shows Robust Immune Responses in Patients With Head & Neck Cancer
PLYMOUTH MEETING, Pa., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today an interim data analysis showing that its INO-3112 DNA-based immunotherapy generated specific T-cell responses and was well tolerated in all evaluable patients with
Read more →INOInovio Pharmaceuticals to Host Third Quarter 2015 Financial Results Conference Call November 9, 2015
PLYMOUTH MEETING, Pa., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the Company will host its third quarter 2015 financial results conference call and live webcast on Monday, November 9 at 8:30 AM ET. A live and archived versio
Read more →INOInovio and Partner Advance MERS Vaccine
Inovio Affiliate GeneOne Files Investigational New Drug Application No vaccine exists for MERS virus, which has killed 40% of those infected PLMOUTH MEETING, Pa., Oct. 19, 2015 (GLOBE NEWSWIRE) -- GeneOne Life Science Inc. (KSE:011000), which partnered with Inovio Pharmaceutica
Read more →INOInovio to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that management will participate at three upcoming investor conferences in October and November: Aegis Growth Conference Brean Capital Life Sciences Summit One-o
Read more →INOInovio Receives $24 Million Option Grant From DARPA to Advance Ebola Program Development
PLYMOUTH MEETING, Pa., Sept. 21, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the U.S. Defense Advanced Research Projects Agency (DARPA) has exercised its option to provide an additional $24 million to support the Inovio-led development
Read more →INOInovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet
PLYMOUTH MEETING, Pa., Sept. 17, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that The Lancet, one of the world's leading medical journals, published a peer-reviewed article detailing the successful results of its phase 2b trial with VGX-3100
Read more →INOInovio's Chief Operating Officer Selected by PharmaVoice as One of the Most Inspirational Leaders in the Global Industry
PLYMOUTH MEETING, Pa., Sept. 15, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that PharmaVoice, one of the leading industry publications in the life sciences industry, has selected Dr. Niranjan Sardesai as one of its 100 most inspiring leader
Read more →INOInovio Pharmaceuticals Announces First Patient Dosed With Universal HIV Vaccine
PLYMOUTH MEETING, Pa., Sept. 8, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the first patient has been dosed in a phase I trial to evaluate safety and tolerability of PENNVAX -GP, Inovio's "universal" DNA vaccine for HIV. This human stu
Read more →INOInovio Pharmaceuticals to Participate in Citi and Rodman & Renshaw Investor Conferences
PLYMOUTH MEETING, Pa., Aug. 26, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President and CEO, will present at Rodman & Renshaw's 17th Annual Global Investment Conference and participate in one-on-one meetings at Citi's 10t
Read more →INOInovio Pharmaceuticals DNA Vaccine Protects 100% Against Deadly MERS Virus in Non-Human Primates
PLYMOUTH MEETING, Pa., Aug. 19, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals (NASDAQ:INO) today announced its DNA vaccine targeting the virulent Middle East Respiratory Syndrome (MERS) induced 100% protection from a live virus challenge in a preclinical study. This medical adv
Read more →INOINOVIO PHARMACEUTICALS ENTERS INTO STRATEGIC CANCER VACCINE COLLABORATION AND LICENSE AGREEMENT WITH MEDIMMUNE Agreement includes clinical-stage INO-3112 HPV cancer vaccine and preclinical collaboration to d
INOVIO PHARMACEUTICALS ENTERS INTO STRATEGIC CANCER VACCINE COLLABORATION AND LICENSE AGREEMENT WITH MEDIMMUNE Agreement includes clinical-stage INO-3112 HPV cancer vaccine and preclinical collaboration to develop additional cancer vaccine Inovio schedules conference call for 8
Read more →INOInovio Pharmaceuticals Reports 2015 Second Quarter Results; Conference Call Will Discuss New Cancer Partnership
PLYMOUTH MEETING, Pa., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended June 30, 2015. Total revenue was $5.3 million and $10.5 million for the three and six months ended June 30, 2015, compared to
Read more →INOInovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration and License Agreement With MedImmune
Agreement Includes Clinical-Stage INO-3112 HPV Cancer Vaccine and Preclinical Collaboration to Develop Additional Cancer Vaccine Candidates Inovio Schedules Conference Call for 8:30am ET Today; Go to inovio.com and Click on "Webcast" Tab PLYMOUTH MEETING, Pa., Aug. 10, 2015 (GL
Read more →INOInovio Pharmaceuticals to Host Second Quarter 2015 Financial Results Conference Call August 10, 2015
PLYMOUTH MEETING, Pa., July 30, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the Company will host its second quarter 2015 financial results conference call and live webcast on Monday, August 10 at 8:30 AM ET. A live and archived versio
Read more →INOInovio Pharmaceuticals' DNA-Based Monoclonal Antibody Protects Animals Against Lethal Challenge
PLYMOUTH MEETING, Pa., July 29, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that its DNA-based monoclonal antibody (dMAb) targeting dengue virus provided protection against a lethal dengue virus challenge in mice. A paper, "Protection against deng
Read more →INOInovio Pharmaceuticals Initiates Clinical Trial of INO-5150 DNA Immunotherapy for Prostate Cancer
PLYMOUTH MEETING, Pa., July 27, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has initiated a phase I trial to evaluate Inovio's DNA immunotherapy in men with biochemically relapsed prostate cancer. The launch of this human trial follo
Read more →INOInovio Pharmaceuticals and European Organization for Research and Treatment of Cancer to Collaborate on Large Phase II Cervical Cancer Trial
PLYMOUTH MEETING, Pa., July 23, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it is collaborating with the European Organization for Research and Treatment of Cancer (EORTC) to evaluate Inovio's immunotherapy, INO-3112, in combination wit
Read more →INOInovio's CEO Appointed to Aspen Institute's Health Innovators Fellowship
PLYMOUTH MEETING, Pa., July 13, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its Chief Executive Officer, Dr. J. Joseph Kim, has been selected by The Aspen Institute to join its Health Innovators Fellowship. Dr. Kim, who co-founded Inovi
Read more →INOInovio Pharmaceuticals CEO Named "Entrepreneur of the Year" by Ernst & Young
PLYMOUTH MEETING, Pa., June 12, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that Inovio's Chief Executive Officer, Dr. J. Joseph Kim, has been selected as the "Entrepreneur of the Year " for Greater Philadelphia by Ernst & Young, a global le
Read more →INOInovio Pharmaceuticals Partners with GeneOne Life Science for MERS Immunotherapy Clinical Development
PLYMOUTH MEETING, Pa., May 27, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced it will advance its DNA vaccine for MERS (Middle East Respiratory Syndrome) into a phase I clinical trial in healthy volunteers in a collaboration with GeneOne Life Science
Read more →INOInovio to Present at Jefferies Healthcare Conference
PLYMOUTH MEETING, Pa., May 26, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that Dr. J. Joseph Kim, President and CEO, will give a corporate presentation at the Jefferies 2015 Healthcare Conference on Thursday, June 4 at 8:30 AM ET. A live a
Read more →INOInovio Initiates Clinical Trial With DNA Immunotherapies to Prevent and Treat Ebola
PLYMOUTH MEETING, Pa., May 12, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that the company has initiated a phase I trial to evaluate safety, tolerability and immune responses of Inovio's DNA immunotherapy for Ebola. In previously published
Read more →INOInovio Pharmaceuticals Reports 2015 First Quarter Financial Results
PLYMOUTH MEETING, Pa., May 11, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) today reported financial results for the quarter ended March 31, 2015. Total revenue was $5.2 million for the three months ended March 31, 2015, compared to $2.4 million for the sam
Read more →INOInovio Pharmaceuticals Closes $87.4 Million Underwritten Financing
PLYMOUTH MEETING, Pa., May 5, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) ("Inovio" or the "Company"), today closed its previously announced underwritten public offering of 10,925,000 shares of the Company's common stock, including 1,425,000 shares of commo
Read more →INOInovio Pharmaceuticals to Report First Quarter 2015 Financial Results May 11, 2015
PLYMOUTH MEETING, Pa., May 1, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that it will host a conference call and live webcast to report its 2015 first quarter financial results on Monday, May 11, 2015 at 8:30 a.m. ET. A live and archived v
Read more →INOInovio Pharmaceuticals Announces Pricing of Public Offering of Common Stock
PLYMOUTH MEETING, Pa., April 30, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) ("Inovio" or the "Company"), today announced the pricing of an underwritten public offering of 9,500,000 shares of common stock for a public offering price of $8.00 per share. The
Read more →INOInovio Pharmaceuticals Announces Public Offering of Common Stock
PLYMOUTH MEETING, Pa., April 29, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) ("Inovio" or the "Company"), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Piper Jaffray & Co. and Stifel are act
Read more →INOInovio Pharmaceuticals and Roche Initiate Clinical Trial for Inovio's DNA Immunotherapy to Treat Chronic Hepatitis B Infection
PLYMOUTH MEETING, Pa., April 21, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that it has initiated a phase I trial to evaluate Inovio's DNA immunotherapy in patients who are chronically infected with hepatitis B. In 2013, Roche and Inovio en
Read more →INOInovio Pharmaceuticals' HPV Immunotherapy Recognized as "Best Therapeutic Vaccine" by World Vaccine Congress
PLYMOUTH MEETING, Pa., April 9, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) today announced that it was recognized with a prestigious industry award at the World Vaccine Congress being held this week in Washington, D.C. The Vaccine Industry Excellence (ViE)
Read more →INOInovio Pharmaceuticals HPV Immunotherapy Activates Robust In Vivo T Cell Responses in Head & Neck Cancer Patients
PLYMOUTH MEETING, Pa., April 9, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today preliminary data showing that its INO-3112 DNA-based immunotherapy generated strong CD8+ T cell responses in 3 of 4 patients with head and neck cancer associated wit
Read more →INOInovio Pharmaceuticals Selected by DARPA to Lead a $45 Million Program to Expedite Development of Novel Products to Prevent and Treat Disease Caused by Ebola
PLYMOUTH MEETING, Pa., April 8, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that the company has been selected to receive a grant from the Defense Advanced Research Projects Agency (DARPA) to lead a collaborative team to develop multiple tre
Read more →INOInovio Pharmaceuticals to Present at Alliance Regenerative Medicine's 2015 Regen Med Investor Day
PLYMOUTH MEETING, Pa., March 19, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that Chief Operating Officer, Dr. Niranjan Sardesai, will present at the 3rd Annual Regen Med Investor Day to be held Wednesday, March 25, 2015 at the Metropolitan
Read more →INOInovio Pharmaceuticals Appoints Scott M. White, M.D. Vice President, Clinical Development -- Infectious Diseases
PLYMOUTH MEETING, Pa., March 18, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today the appointment of Scott M. White, M.D. as Vice President, Clinical Development - Infectious Diseases. Dr. White will be responsible for advancing Inovio's infectio
Read more →INOInovio Pharmaceuticals Reports 2014 Fourth Quarter and Year End Financial Results
PLYMOUTH MEETING, Pa., March 16, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) today reported financial results for the fourth quarter and year ended December 31, 2014. Total revenue was $2.5 million and $10.5 million for the quarter and year ended December
Read more →INOInovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National Institute of Allergy and Infectious Diseases
PLYMOUTH MEETING, Pa., March 16, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that the company and its academic collaborators, including the University of Pennsylvania (UPenn), were awarded a new five-year $16 million Integrated Preclinical/C
Read more →INOImmediate Release Inovio Pharmaceuticals Welcomes Nancy Wysenski To Its Board of Directors
Pharmaceuticals Welcomes Nancy Wysenski To Its Board of Directors PLYMOUTH MEETING, Pa. March 5, 2014 Inovio Pharmaceuticals, Inc. (NASDAQ: INO), a leader in the development of immunotherapies for cancer and infectious diseases, announced today that Nancy Wysenski joined its B
Read more →INOInovio Pharmaceuticals to Report Fourth Quarter and Year End 2014 Financial Results on March 16, 2015
PLYMOUTH MEETING, Pa., March 6, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that it will host a conference call and live webcast to report its 2014 fourth quarter and year-end financial results on Monday, March 16, 2015 at 8:30 a.m. ET. A l
Read more →INOInovio Pharmaceuticals Welcomes Nancy Wysenski to Its Board of Directors
PLYMOUTH MEETING, Pa., March 5, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO), a leader in the development of immunotherapies for cancer and infectious diseases, announced today that Nancy Wysenski joined its Board of Directors. Ms. Wysenski, a commercial pha
Read more →INOInovio Pharmaceuticals Appoints Dr. Mark Gelder to Lead Clinical Development of Cervical Dysplasia and Cancer Programs
PLYMOUTH MEETING, Pa., Jan. 29, 2015 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today it has appointed Mark Stephen Gelder, M.D. as Vice President, Clinical Development. Dr. Gelder will be responsible for planning and executing Inovio's clinical developm
Read more →INOInovio Pharmaceuticals
PLYMOUTH MEETING, Pa., Jan. 7, 2015 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced that President and CEO, Dr. J. Joseph Kim, will present a company overview at the 2015 Biotech Showcase Conference on Monday, January 12 in San Francisco, CA. Dr. Kim's prese
Read more →INOInovio Pharmaceuticals HIV Immunotherapy Shows Characteristics Considered Vital to Treating HIV
PLYMOUTH MEETING, Pa., Jan. 6, 2015 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that results from a 12-patient phase I study of Inovio's HIV immunotherapy, PENNVAX®-B, in HIV-infected patients revealed that immune response characteristics generated
Read more →INOInovio Pharmaceuticals Initiates DNA Immunotherapy Trial for Breast, Lung and Pancreatic Cancers
PLYMOUTH MEETING, Pa., Dec. 18, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced it has initiated a phase I trial of its hTERT DNA immunotherapy (INO-1400) alone or in combination with Inovio's IL-12 immune activator (INO-9012) in adults with breast, lung
Read more →INOInovio Pharmaceuticals Appoints Zane Yang, M.D. Vice President, Clinical Development, Oncology
PLYMOUTH MEETING, Pa., Dec. 17, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Zane Yang, M.D. as Vice President, Clinical Development, Oncology. In this position, he will be responsible for advancing Inovio's oncology portfolio
Read more →INOInovio Pharmaceuticals, Inc. (Nasdaq: INO) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, Nov. 24, 2014 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO), a company dedicated to revolutionizing the fight against cancer and infectious diseases will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Dr. J. Joseph Kim, Chief Ex
Read more →INOInovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market
PLYMOUTH MEETING, Pa., Nov. 24, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that Dr. J. Joseph Kim, President and CEO of Inovio Pharmaceuticals, will be joined by members of the company's board and management team to ring the Nasdaq Opening Bel
Read more →INOInovio Pharmaceuticals Melanoma DNA Immunotherapy Inhibits Tumor Growth and Increases Survival in Preclinical Study
PLYMOUTH MEETING, Pa., Nov. 20, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today its newest DNA-based cancer immunotherapy targeting melanoma induced a robust and broad immune response in animals and directed cancer-killing T cells against tumors. T
Read more →INOInovio Pharmaceuticals to Independently Develop Prostate Cancer Immunotherapy; Will Maintain Collaboration and License Agreement with Roche for Inovio
PLYMOUTH MEETING, Pa., Nov. 17, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the company and Roche have terminated their 2013 collaboration, option, and license agreement to co-develop INO-5150, Inovio's DNA immunotherapy targeting prostate canc
Read more →INOInovio to Present at Upcoming Investor Conferences
PLYMOUTH MEETING, Pa., Nov. 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that Dr. J. Joseph Kim, President & CEO, will present a corporate overview at the upcoming Stifel Healthcare Conference, Brean Capital Life Science Conference, and Pipe
Read more →INOInovio Pharmaceuticals Reports 2014 Third Quarter Financial Results
PLYMOUTH MEETING, Pa., Nov. 10, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today reported financial results for the quarter ended September 30, 2014. Total revenue was $1.8 million and $8.0 million for the three and nine months ended September 30, 2014, comp
Read more →INOInovio Pharmaceuticals to Report Third Quarter 2014 Financial Results on November 10, 2014
PLYMOUTH MEETING, Pa., Nov. 4, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it will host a conference call and live webcast to report its third quarter 2014 financial results on Monday, November 10, 2014, at 8:00 a.m. ET. Management will di
Read more →INOInovio Pharmaceuticals' CEO Dr. J. Joseph Kim Interviewed by The Life Sciences Report
SAN FRANCISCO, CA--(Marketwired - Oct 30, 2014) - Since Edward Jenner's development of the smallpox vaccine in the late 1790s, humankind has enjoyed the benefit of immunization, which has saved many millions of lives. Today, Inovio Pharmaceuticals Inc. (NYSE MKT: INO) is in the f
Read more →INOInovio Pharmaceuticals, MedImmune and the University of Pennsylvania Partner to Combat Influenza and Antibiotic Resistant Bacteria
PLYMOUTH MEETING, Pa., Oct. 21, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the Defense Advanced Research Projects Agency (DARPA) has awarded $12.2 million for a collaborative study that will be conducted by scientists from the Perelman School
Read more →INOInovio Pharmaceuticals Appoints Vice President of Commercial Development
PLYMOUTH MEETING, Pa., Sept. 30, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the appointment of Jennifer Laux as Vice President, Commercial. In this position she will be charged with the development of Inovio's commercialization strategy for it
Read more →INOInovio Pharmaceuticals Ebola Vaccine Moving into Human Trial with GeneOne Life Science
PLYMOUTH MEETING, Pa., Sept. 24, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced it will advance its DNA vaccine for Ebola into a phase I clinical trial in a collaboration with GeneOne Life Science Inc. (KSE: 011000), an international DNA vaccine manufac
Read more →INOInovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers
PLYMOUTH MEETING, Pa., Sept. 22, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today it has initiated a phase I clinical trial in patients with aerodigestive cancers. The trial will evaluate the safety, tolerability, and immunogenicity of INO-3106. Thi
Read more →INOInovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange
PLYMOUTH MEETING, Pa., Sept. 15, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it has met the stringent listing criteria for the NASDAQ Global Select Market and effective today has transferred to this U.S. stock exchange from the NYSE MKT. T
Read more →INOInovio Pharmaceuticals to List on NASDAQ
PLYMOUTH MEETING, Pa., Sept. 4, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it has met the listing criteria for the NASDAQ Global Select Market and will transfer its U.S. stock exchange listing from the NYSE MKT to the NASDAQ Global Sele
Read more →INOInovio Pharmaceuticals Reports 2014 Second Quarter Financial Results
PLYMOUTH MEETING, Penn., Aug. 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to
Read more →INOInovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014
PLYMOUTH MEETING, Pa., Aug. 1, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it will host a conference call to report its second quarter 2014 financial results on Monday, August 11, 2014 at 9:00 AM ET. CEO Dr. J. Joseph Kim and CFO Peter K
Read more →INOInovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial
PLYMOUTH MEETING, Pa., July 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3
Read more →INOInovio Pharmaceuticals Added To Russell Global, Russell 2000® and Russell Microcap® Indexes
PLYMOUTH MEETING, Pa., July 1, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced that it has been added to the Russell Global, Russell 2000 and Russell Microcap Indexes. Each June, Russell realigns its family of global equity indexes to reflect market ch
Read more →INOInovio Pharmaceuticals Initiates Cervical Cancer Clinical Trial
BLUE BELL, Pa., June 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in
Read more →INOInovio Pharmaceuticals Broadens its Intellectual Property Portfolio from the University of Pennsylvania
BLUE BELL, Pa., June 17, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide rights to technology and intellectual property for novel synthetic therapies agai
Read more →INOInovio Pharmaceuticals to Present at Upcoming Healthcare Conferences
BLUE BELL, Pa., June 16, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that President & CEO, Dr. J. Joseph Kim, will participate in a panel at the Piper Jaffray GenomeRx Symposium on June 23 to discuss Inovio's leadership in the advancement of
Read more →INOInovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology
BLUE BELL, Pa., June 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) wishes to clarify that a third party article published on June 10, 2014, was misrepresentative of facts and can only be taken as malicious. The referenced article does not reflect the progr
Read more →INOInovio Pharmaceuticals Initiates Immune Therapy Trial for Head & Neck Cancer Caused by HPV
BLUE BELL, Pa., June 10, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavi
Read more →INOInovio Pharmaceuticals Announces Reverse Stock Split Date
BLUE BELL, Pa., May 30, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-revers
Read more →INOInovio Pharmaceuticals Subsidiary Sells Animal Health Assets
BLUE BELL, Pa., May 27, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its 90%-owned subsidiary, VGX Animal Health, Inc. (VAH), has concluded an agreement for the sale of its animal health assets to Plumbline Life Sciences, Inc. (PLS) of Ko
Read more →INOInovio Pharmaceuticals Breakthrough DNA-Based Monoclonal Antibody Therapy Completely Protects Animals From Lethal Viral Challenge
BLUE BELL, Pa., May 27, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge. In this preclinical stud
Read more →INOInovio Pharmaceuticals Announces 1 For 4 Reverse Split
BLUE BELL, Pa., May 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that at the Company's Annual General Meeting held May 22, 2014, the Company's shareholders approved the proposal of a reverse split of the Company's common stock. The Company
Read more →INOInovio Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference
BLUE BELL, Pa., May 21, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. Joseph Kim, President and CEO, will give a corporate presentation at the Jefferies 2014 Global Healthcare Conference taking place June 2-5 at the Grand Hyatt Hotel i
Read more →INOInovio Pharmaceuticals Acquires Early Stage DNA Therapies to Treat Alzheimer
BLUE BELL, Pa., May 13, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today it acquired worldwide rights (excluding China) for early preclinical therapies addressing Alzheimer's disease and multiple sclerosis based on the academic research of Dr. Bin
Read more →INOInovio Pharmaceuticals Reports 2014 First Quarter Financial Results
BLUE BELL, Pa., May 12, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended March 31, 2014. Total revenue was $2.4 million for the three months ended March 31, 2014, compared to $1.5 million for the same period
Read more →INOInovio Pharmaceuticals Continues Building Its Senior Team With the Appointment of VP of Quality
BLUE BELL, Pa., April 1, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced the appointment of E.J. Brandreth as Vice President of Quality. He will be responsible for all quality and compliance functions for a company that is moving forward with num
Read more →INOInovio Pharmaceuticals Recognized with "Best Therapeutic Vaccine" Award at World Vaccine Congress 2014
BLUE BELL, Pa., March 26, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that it was recognized with three industry awards at the World Vaccine Congress, which is being held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awa
Read more →INOInovio Pharmaceuticals Reports 2013 Fourth Quarter and Year End Financial Results
BLUE BELL, Pa., March 17, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the fourth quarter and year ended December 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013
Read more →INOInovio Pharmaceuticals to Report Fourth Quarter and Year End 2013 Financial Results on March 17, 2014
BLUE BELL, Pa., March 12, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it will host a conference call and live webcast to report its fourth quarter and year end 2013 financial results on Monday, March 17, 2014 at 8:30 a.m. ET. Management
Read more →INOInovio Pharmaceuticals Closes $63.3 Million Underwritten Financing
Inovio Pharmaceuticals Closes $63.3 Million Underwritten Financing BLUE BELL, PA March 4, 2014 Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) ( Inovio or the Company ), today closed its previously announced underwritten public offering of 21,810,900 shares of the Company s common
Read more →INOInovio Pharmaceuticals, Inc. Overview We are engaged in the discovery and development of a new generation of vaccines and immune therapies, called synthetic vaccines, focused on cancers and infectious diseases. Our DNA-b
Inovio Pharmaceuticals, Inc. We are engaged in the discovery and development of a new generation of vaccines and immune therapies, called synthetic vaccines, focused on cancers and infectious diseases. Our DNA-based SynCon technology is designed to provide universal protection
Read more →INOInovio Pharmaceuticals to Present at Cowen and Company 34th Annual Health Care Conference
BLUE BELL, Pa., Feb. 19, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that President and CEO, Dr. J. Joseph Kim, will present a corporate overview of the company at the Cowen and Company 34th Annual Health Care Conference in Boston, MA. Cowen
Read more →INOInovio Pharmaceuticals Bolsters Research and Clinical Development Leadership as it Advances Cancer & Infectious Disease Immunotherapies
BLUE BELL, Pa., Feb. 18, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has expanded its senior management team with two appointments to help advance the company's growing pipeline of preclinical and clinical DNA vaccines. Inovio has appointe
Read more →INOInovio Pharmaceuticals Invited To Ring the Opening Bell® at the New York Stock Exchange on February 12
BLUE BELL, Pa., Feb. 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it has been invited by the New York Stock Exchange to ring the Opening Bell® tomorrow, February 12th, to mark the beginning of an exciting year for the company in which
Read more →INOInovio Pharmaceuticals to Present at BIO CEO & Investor Conference
BLUE BELL, Pa., Jan. 30, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that President and CEO, Dr. J. Joseph Kim, will present a corporate overview of the company at the 16th Annual BIO CEO & Investor Conference in New York, NY. BIO CEO & Inve
Read more →INOInovio Pharmaceuticals Unveils Potent New Immune Activator
BLUE BELL, Pa., Jan. 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 (IL-33), that in combination with optimized DNA vaccines delivered by electroporatio
Read more →INOInovio Pharmaceuticals to Present at Biotech Showcase 2014 Investor Conference
BLUE BELL, Pa., Jan. 6, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. J. Joseph Kim, President and CEO, will present a corporate overview of the company at the Biotech Showcase 2014 investor conference in San Francisco, CA. Biotech Sh
Read more →INOCEO Dr. Joseph Kim to Discuss Inovio
BLUE BELL, Pa., Dec. 11, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. J. Joseph Kim, President and CEO, has been invited to participate on an expert panel titled, Ovarian & Cervical Cancer – Evaluating the Role of Immunotherapy Explor
Read more →INOInovio Pharmaceutical
BLUE BELL, Pa., Nov. 20, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, demonst
Read more →INOInovio Pharmaceuticals CEO Appointed to International Vaccine Institute Board of Trustees
BLUE BELL, Pa., Nov. 19, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) reported that the International Vaccine Institute (IVI) appointed Inovio's President and CEO, Dr. J. Joseph Kim, to the IVI Board of Trustees where he will serve a three-year term to overse
Read more →INOInovio Pharmaceuticals CEO Receives 2013 Drug Discovery & Achievement Award
BLUE BELL, Pa., Nov. 14, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its President & CEO, Dr. J. Joseph Kim, has been selected to receive the 2013 Achievement in Drug Discovery and Development Award from the Korean American Society in Bi
Read more →INOInovio Pharmaceuticals Reports 2013 Third Quarter Financial Results
BLUE BELL, Pa., Nov. 12, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended September 30, 2013. Total revenue was $9.5 million and $11.7 million for the three and nine months ended September 30, 2013, compared
Read more →INOInovio Pharmaceuticals to Report Third Quarter 2013 Financial Results on November 12, 2013
BLUE BELL, Pa., Nov. 4, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it will host a conference call and live webcast to report its third quarter 2013 financial results on Tuesday, November 12, 2013, at 8:30 a.m. ET. Management will provid
Read more →INOInovio Pharmaceuticals Therapeutic Vaccine for Hepatitis C Enters Phase I Clinical Trial
BLUE BELL, Pa., Oct. 21, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HC
Read more →INOInovio Pharmaceuticals to Participate in Immunotherapy Panel and Present at the 12th Annual BIO Investor Forum
BLUE BELL, Pa., Oct. 1, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. J. Joseph Kim, President and CEO, was invited to participate in a panel discussion at the 12th Annual BIO Investor Forum. In a panel titled, The Ultimate Rejection:
Read more →INOInovio Pharmaceuticals Targets Transformation of Monoclonal Antibody Therapies
BLUE BELL, Pa., Sept. 24, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today the publication of a peer-reviewed paper demonstrating the success of its new DNA plasmid technology in generating therapeutic monoclonal antibodies. In this study in mice,
Read more →INOInovio Pharmaceuticals to Present at Investor Conferences and Town Hall Los Angeles
BLUE BELL, Pa., Sept. 18, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. J. Joseph Kim, President and CEO, will be presenting an overview of the company at the Aegis Capital Corp. Healthcare Conference and BioCentury's 20th Annual NewsM
Read more →INORoche and Inovio Pharmaceuticals partner on Inovio
BASEL, Switzerland and BLUE BELL, Pa., Sept. 10, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that they have entered into an exclusive worldwide license agreement to research, develop and commercialize In
Read more →INOBasel, Switzerland and Blue Bell, PA, USA 10 September 2013 Roche and Inovio Pharmaceuticals partner on Inovio s prostate cancer and hepatitis B immunotherapy products Roche (SIX: RO, ROG; OTCQX: RHHBY) and
Basel, Switzerland and Blue Bell, PA, USA 10 September 2013 Roche and Inovio Pharmaceuticals partner on Inovio s prostate cancer and hepatitis B immunotherapy products Roche (SIX: RO, ROG; OTCQX: RHHBY) and Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that they
Read more →INOInovio Pharmaceuticals to Hold Investor Conference Call to Discuss Partnership with Roche
BLUE BELL, Pa., Sept. 10, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) will hold a conference call with investors this morning, Tuesday September 10, at 8:00 a.m. (ET) to discuss its partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) which the companies anno
Read more →INOInovio Pharmaceuticals Reports 2013 Second Quarter Financial Results
BLUE BELL, Pa., Aug. 9, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended June 30, 2013. Total revenue was $786,000 and $2.2 million for the three and six months ended June 30, 2013, compared to $436,000 and
Read more →INOInovio Pharmaceuticals Responds to Market Activity
BLUE BELL, Pa., Aug. 6, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in view of the unusual market activity in the company's stock, the Exchange has contacted the company in accordance with its usual practice. The company stated that its
Read more →INOSynthetically Optimized HIF-1 Alpha DNA Delivered with Inovio
BLUE BELL, Pa., July 18, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that the use of its proprietary electroporation technology significantly enhanced the ability of a DNA therapy to stimulate blood vessel growth, which may be beneficial for
Read more →INOInovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study
BLUE BELL, Pa., May 14, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of Inovio's SynCon® DNA vaccine against Ebola and Marburg filoviruses, labeled "Category A" bioterrorism agents by the U.S. government, the vaccin
Read more →INOInovio Pharmaceuticals Reports 2013 First Quarter Financial Results
BLUE BELL, Pa., May 10, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended March 31, 2013. Total revenue was $1.5 million for the three months ended March 31, 2013, compared to $1.7 million for the same period
Read more →INOInovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
BLUE BELL, Pa., April 18, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its SynCon® universal H1N1 influenza vaccine generated protective antibody levels comparable to a current FDA-approved seasonal influenza vaccine against a currently c
Read more →INOInovio Pharmaceuticals Reports 2012 Fourth Quarter and Year End Financial Results
BLUE BELL, Pa., March 18, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSEAMEX: INO) today reported financial results for the fourth quarter and year ended December 31, 2012. Total revenue was $1.1 million and $4.1 million for the quarter and year ended December 31, 2012,
Read more →INOInovio Pharmaceuticals Closes $15.1 Million Offering of Common Stock and Warrants
BLUE BELL, Pa., March 12, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that it has closed an underwritten offering of 27,377,266 shares of its common stock and warrants to purchase up to 13,688,633 shares of common stock at a combined price of
Read more →INOInovio Pharmaceuticals Prices $15.1 Million Offering of Common Stock and Warrants
BLUE BELL, Pa., March 7, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that it has priced an underwritten offering of 27,377,266 shares of its common stock and warrants to purchase up to 13,688,633 shares of common stock at a combined price to
Read more →INOInovio Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
NEW YORK, Feb. 11, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that their February 7th RetailInvestorConferences.com presentation is now available for on-demand viewing. LINK: www.retailinvestorconferences.com > red "register/ watch event no
Read more →INOInovio Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th
NEW YORK, Feb. 5, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that CEO Dr. J. Joseph Kim will present an overview of the company at RetailInvestorConferences.com. DATE: February 7, 2013 LINK: www.retailinvestorconferences.com > red "registe
Read more →INOInovio Pharmaceuticals to Initiate Clinical Trial for its Hepatitis C Therapeutic Vaccine (INO-8000) Later this Year
BLUE BELL, Pa., Jan. 9, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) and its development partner VGX International, Inc. (KSE: 011000) will move Inovio's hepatitis C (HCV) DNA vaccine into a phase I/IIa clinical trial by the end of 2013. This advancement is b
Read more →INOPATH Malaria Vaccine Initiative and Inovio Pharmaceuticals Partner to Accelerate Development of Malaria Vaccines and Innovative Delivery Technologies
WASHINGTON and BLUE BELL, Pa., Jan. 7, 2013 /PRNewswire/ -- The PATH Malaria Vaccine Initiative (MVI) and Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced a follow-on collaboration to advance malaria vaccine development and new vaccination delivery technologies. Resea
Read more →INOInovio Pharmaceuticals to Present at Biotech Showcase 2013 Investor Conference
BLUE BELL, Pa., Dec. 20, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO), which is revolutionizing vaccines to combat cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO, will be presenting a corporate overview of the compa
Read more →INOInovio's Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) reported interim results of a phase I trial that showed that a single dose of its H1N1 universal SynCon® ...
BLUE BELL, Pa., Dec. 10, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) reported interim results of a phase I trial that showed that a single dose of its H1N1 universal SynCon® flu vaccine followed with a dose of a seasonal flu vaccine generated protective immu
Read more →INOInovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
BLUE BELL, Pa., Dec. 6, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that preliminary results of a phase II clinical trial to treat leukemia with a WT1 DNA vaccine delivered with Inovio's proprietary electroporation delivery system showed robu
Read more →INOInovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
BLUE BELL, Pa., Nov. 26, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that testing of multiple synthetic vaccine constructs for cytomegalovirus (CMV) induced robust T cells in mice, demonstrating the potential for a SynCon® DNA vaccine to trea
Read more →INOInovio Expands Synthetic Vaccine Intellectual Property License With University of Pennsylvania
BLUE BELL, Pa., Nov. 14, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has expanded its existing license agreement with the University of Pennsylvania (UPenn), adding worldwide rights to technology and intellectual property for novel synthetic vaccines against
Read more →INOInovio Therapeutic Hepatitis B Vaccine Killer T Cells Demonstrate Potential to Clear HBV in Liver
BLUE BELL, Pa., Nov. 12, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its synthetic hepatitis B (HBV) therapeutic vaccine generated strong T cell responses that eliminated targeted liver cells in mice. This data points to the DNA vaccine'
Read more →INOInovio Pharmaceuticals Reports 2012 Third Quarter Financial Results
BLUE BELL, Pa., Nov. 7, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSEAMEX: INO) today reported financial results for the quarter ended September 30, 2012. Total revenue was $855,000 and $3.0 million for the three and nine months ended September 30, 2012, compared to $2
Read more →INOInovio Pharmaceuticals Animal Health Subsidiary
BLUE BELL, Pa., Oct. 15, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its majority-owned subsidiary, VGX Animal Health, has received approval to market LifeTide® SW 5.0, the world's first approved growth hormone releasing hormone (GHRH) t
Read more →INOInovio Pharmaceuticals Named Best Mid-Stage Product Development Company by the Philadelphia Business Journal
BLUE BELL, Pa., Oct. 5, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has been named Best Mid-Stage Product Development Company by the Philadelphia Business Journal as part of the Journal's Life Sciences Awards, an annual program recognizing the region's "medi
Read more →INOInovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
BLUE BELL, Pa., Sept. 18, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that J. Joseph Kim, Ph.D., President and CEO, will present and participate in a panel at BIOX, Noble Financial Capital Markets' Life Sciences Exposition to be held at the U
Read more →INOInovio Pharmaceuticals Takes Major Stride Toward Universal Influenza Vaccine
BLUE BELL, Pa., Sept. 6, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that the interim analysis of its SynCon® universal H1N1 influenza vaccine showed that it generated protective HAI titers against some of the most prevalent strains of H1N1 i
Read more →INOInovio Pharmaceuticals to Present at Liolios, Stifel, and Rodman & Renshaw Investor Conferences
BLUE BELL, Pa., Aug. 27, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that senior executives of Inovio will present overviews of the company at the Stifel Nicolaus Healthcare Conference, Liolios Group Gateway Conference, and the Rodman & Rensh
Read more →INOInovio Pharmaceuticals Reports 2012 Second Quarter Financial Results
BLUE BELL, Pa., Aug. 9, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended June 30, 2012. Total revenue was $436,000 and $2.1 million for the three and six months ended June 30, 2012, compared to $2.4 million
Read more →INOInovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
BLUE BELL, Pa., July 10, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that the first patients have been treated in a clinical trial evaluating immune responses in elderly adults immunized with Inovio's H1N1 SynCon® universal influenza vaccine.
Read more →INOInovio Pharmaceuticals to Present at JMP Investor Conference
BLUE BELL, Pa., July 9, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. J. Joseph Kim, President and CEO, will present an overview of the company at the JMP Securities Healthcare Conference. 7th Annual JMP Securities Healthcare Conferen
Read more →INOInovio Pharmaceuticals Appoints International Management Expert Dr. Angel Cabrera to its Board of Directors
BLUE BELL, Pa., June 18, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has appointed Angel Cabrera, Ph.D., to its Board of Directors. Dr. Cabrera is outgoing president of the Thunderbird School of Global Management, widely regarded as the world's leading gradu
Read more →INOImmediate Release CONTACTS: Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 267-440-4211 Inovio Implements New ATM Agreement
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 267-440-4211 Inovio Implements New ATM Agreement BLUE BELL, PA June 1, 2012 Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it has entered into a
Read more →INOInovio Implements New ATM Agreement
BLUE BELL, Pa., June 1, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it has entered into a sales agreement with Cowen and Company, LLC, under which Inovio may from time to time offer and sell common stock with aggregate proceeds of up to
Read more →INOInovio Pharmaceuticals to Present at SPI 2012
BLUE BELL, Pa., May 15, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. J. Joseph Kim, President and CEO, will present an overview of the company and participate in a panel discussion at SPI 2012 Science, Partnering, and Investment Forum
Read more →INOInovio Pharmaceuticals Reports 2012 First Quarter Financial Results
BLUE BELL, Pa., May 9, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSEAMEX: INO) today reported financial results for the quarter ended March 31, 2012. Total revenue was $1.7 million for the three months ended March 31, 2012, compared to $3.1 million for the same period
Read more →INOInovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
BLUE BELL, Pa., May 1, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSEAMEX: INO) announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,168,769, covering Inovio's SynCon® vaccine for cervical dysplasias and cancers caused by human pap
Read more →INOInovio Pharmaceuticals Receives Defense Department Funding for Bioterrorism-Related Synthetic Vaccine Program
BLUE BELL, Pa., April 2, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today it has received a U.S. Department of Defense Small Business Innovation Research Grant to advance the development of a low-cost, non-invasive surface electroporation (EP) de
Read more →INOInovio Appoints Retired Merck Vaccines President Dr. Adel Mahmoud to its Board of Directors
BLUE BELL, Pa., Mar. 27, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today Dr. Adel Mahmoud, a global infectious disease and vaccines expert, has been appointed to Inovio's Board of Directors. During his long tenure at Merck & Co., Dr. Mahmoud was
Read more →INOInovio Receives U.S. Patent for SynCon® H1N1 Influenza Universal Vaccine
BLUE BELL, Pa., March 26, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSEAMEX: INO) announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,133,723, covering Inovio's SynCon® universal vaccine related to H1N1 influenza. The patent gran
Read more →INOInovio Appoints Vaccine Industry Leader to its Scientific Advisory Board
BLUE BELL, Pa., March 7, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that a global vaccine industry leader has joined the company's Scientific Advisory Board. Dr. Anthony Ford-Hutchinson, with over 30 years' experience in vaccine development
Read more →INOInovio Therapeutic Vaccine for Head & Neck and Other HPV-Related Cancers Induces Robust T-Cell Immune Response in Mice
BLUE BELL, Pa., March 5, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSEAMEX: INO) announced today that its SynCon® therapeutic vaccine for human papillomavirus (HPV) types 6 and 11, which are associated with head & neck cancers and genital warts, among other conditions,
Read more →INOInovio Pharmaceuticals to Present at Cowen and ROTH Investor Conferences
BLUE BELL, Pa., Feb. 28, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that Inovio management will present an overview of the company at investment conferences hosted by Cowen Group and ROTH Capital Partners. Cowen 32nd Annual Health Care Con
Read more →INOInovio Researchers Successfully Demonstrate RNA Drug Delivery via Electroporation
BLUE BELL, Pa., Feb. 22, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that its next generation surface skin electroporation technology was successfully used to significantly enhance the delivery of small interfering RNA (siRNA) molecules to s
Read more →INOInovio's Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that David B. Weiner, Ph.D., Professor, Department of Pathology & Laboratory Medicine,...
BLUE BELL, Pa., Feb. 21, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that David B. Weiner, Ph.D., Professor, Department of Pathology & Laboratory Medicine, University of Pennsylvania, and Chairman of Inovio's Scientific Advisory Board, has b
Read more →INOInovio Pharmaceuticals Moves Closer to "Universal" Influenza Vaccine by Demonstrating Protective Immune Responses Against Multiple H3N2 and Type B Strains in Animal Studies
BLUE BELL, Pa., Jan. 31, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that its synthetic vaccines for influenza Type A H3N2 and Type B achieved protective antibody responses in immunized animals against multiple unmatched strains. Inovio prev
Read more →INOInovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
BLUE BELL, Pa., Jan. 11, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), which is revolutionizing vaccines to fight cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO, will present an overview of the company at Noble Fin
Read more →INOInovio Pharmaceuticals to Present at Biotech Showcase Investor Conference
BLUE BELL, Pa., Jan. 5, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), which is revolutionizing vaccines to fight cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO, will present an overview of the company at the Biotec
Read more →INOInovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
BLUE BELL, Pa., Jan. 4, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), which is revolutionizing vaccines to fight cancers and infectious diseases, announced today that it has promoted Niranjan Y. Sardesai, Ph.D., from Senior Vice President Research and Develo
Read more →INOInvestors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.com Media: Jeff Richardson, Richardson & Associates 805-491-8313 jeff@richardsonglobalpr.com Inovi
Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.com Media: Jeff Richardson, Richardson & Associates 805-491-8313 jeff@richardsonglobalpr.com Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer BLUE BELL, PA January 4, 2012
Read more →INOInovio Pharmaceuticals to Present at Oppenheimer Investor Conference
BLUE BELL, Pa., Dec. 12, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO, will present an overview of the company at the O
Read more →INOInovio Pharmaceuticals Closes $4.0 Million Underwritten Financing
BLUE BELL, Pa., Dec. 7, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that it has closed an underwritten public offering of 7,699,712 shares of its common stock a
Read more →INOInovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
BLUE BELL, Pa., Nov. 7, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSEAMEX: INO) today reported financial results for the quarter ended September 30, 2011. Total revenue was $2.6 million and $8.2 million for the three and nine months ended September 30, 2011, compared t
Read more →INOInovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
BLUE BELL, Pa., Oct. 31, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that VGX-3100, its investigational SynCon® vaccine for treating cervical dysplasia and canc
Read more →INOInovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
BLUE BELL, Pa., Oct. 10, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its
Read more →INOInovio Pharmaceuticals to Present at Scientific Conferences
BLUE BELL, Pa., Sept. 30, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that scientists, advisors and collaborators of the company will make presentati
Read more →INOInovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines
BLUE BELL, Pa., Sept. 27, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has entered into a Cooperative Research and Development Agreement (CR
Read more →INOInovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
BLUE BELL, Pa., Sept. 14, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical stu
Read more →INOInovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
BLUE BELL, Pa., Sept. 6, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has expanded its scientific advisory board with the appointment of two prominen
Read more →INOInovio Pharmaceuticals to Present at Investor Conferences
BLUE BELL, Pa., Aug. 31, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. Joseph Kim, President and CEO, will present an overvie
Read more →INOInovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
BLUE BELL, Pa., Aug. 8, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSEAMEX: INO) today reported financial results for the quarter ended June 30, 2011. Total revenue was $2.4 million and $5.5 million for the three and six months ended June 30, 2011, compared to $1.1 mill
Read more →INOInovio Pharmaceuticals Demonstrates T Cell Immune Response Durability with Fourth Dose of Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
BLUE BELL, Pa., July 15, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of T cell immune responses
Read more →INOInovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
BLUE BELL, Pa., July 14, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that significant T cell and antibody responses were generated i
Read more →INOInovio Expands DNA Vaccine Intellectual Property License With the University of Pennsylvania
BLUE BELL, Pa., July 7, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has expanded its existing license agreement with the Uni
Read more →INOInovio Pharmaceuticals Synthetic DNA Vaccine Protects Against HIV in Non-Human Primates
BLUE BELL, Pa., July 5, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that novel data from a preclinical study of its SynCon™ DNA vacc
Read more →INOInvestors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.com Media: Jeff Richardson, Richardson Associates 805-491-8313 jeff@richardsonglobalpr.com Inovio
Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.com Media: Jeff Richardson, Richardson Associates 805-491-8313 jeff@richardsonglobalpr.com Inovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board BLUE BE
Read more →INOInovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board
BLUE BELL, Pa., July 1, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. Avtar Dhillon has become non-executive Chairman of the
Read more →INOVGX Animal Health DNA Vaccine for Dogs Could Reduce Tumor Growth and Increase Survival
BLUE BELL, Pa., June 17, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that its subsidiary VGX Animal Health, Inc., a developer of DNA-based vaccines and therapies for companion and food animals, has achieved strong T cell responses from VAH-5
Read more →INOInovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011
BLUE BELL, Pa., June 9, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its majority-owned subsidiary, VGX Animal Health, Inc, will
Read more →INOInovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
BLUE BELL, Pa., May 17, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company will highlight its DNA vaccines and electropora
Read more →INOInovio Pharmaceuticals Reports 2011 First Quarter Financial Results
BLUE BELL, Pa., May 11, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSEAMEX: INO) today reported financial results for the quarter ended March 31, 2011. Total revenue for the quarter ended March 31, 2011, was $3.1 million, compared with $1.4 million for the same period i
Read more →INOInovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
BLUE BELL, Pa., May 9, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced
Read more →INOArticle in Current Opinion in Immunology Journal Declares Coming "Decade of DNA Vaccines"
BLUE BELL, Pa., May 5, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the prestigious journal Current Opinion in Immunology has pu
Read more →INOInovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C
BLUE BELL, Pa., April 18, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. (E
Read more →INOInovio Pharmaceuticals Receives U.S. DOD Small Business Innovation Research Grant for Multi-Vaccine DNA Delivery Device Development
BLUE BELL, Pa., March 21, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has received a U.S. Department of Defense Small Busine
Read more →INOInovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
BLUE BELL, Pa., March 17, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSEAMEX: INO) today reported financial results for the fourth quarter and year ended December 31, 2010. Total revenue was $2.4 million and $6.1 million for the quarter and year ended December 31, 2010,
Read more →INOInovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
BLUE BELL, Pa., Mar. 7, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it is initiating a Phase II clinical trial for its VGX-3100
Read more →INOInovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
BLUE BELL, Pa., March 3, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO, will present a compa
Read more →INOInovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
BLUE BELL, Pa., Feb. 24, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO will present a compan
Read more →INOInovio Pharmaceuticals to Present at Partnering and Scientific Conferences
BLUE BELL, Pa., Feb. 22, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company will make presentations at two partnering and
Read more →INOInovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
BLUE BELL, Pa., Feb. 8, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO, will present a corpor
Read more →INOUniversity of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
BLUE BELL, Pa., Jan. 31, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial (WIN Trial)
Read more →INOInovio Pharmaceuticals Closes $24.3 Million Registered Offering
BLUE BELL, Pa., Jan. 27, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the closing of the sale to a single institutional investor of 2
Read more →INO: Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 805-491-8313 Inovio Biomedical Board of Directors Adds Two New Memb
Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 805-491-8313 Inovio Biomedical Board of Directors Adds Two New Members David J. Williams, former chairman & CEO of the vaccines business of Sanofi- Aventis Group, and K
Read more →INOImmediate Release CONTACTS : Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 805-491-8313 Inovio Announces $30 Million Registered Direct Offering
CONTACTS : Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 805-491-8313 $30 Million Registered Direct Offering SAN DIEGO, CA July 30, 2009 Inovio Biomedical Corporation (NYSE AMEX: INO) ( Inovio ), a leader in DNA
Read more →INOImmediate Release CONTACTS : Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 805-491-8313 Inovio Biomedical and VGX Pharmaceuticals Stockholders Ove
Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 805-491-8313 Inovio Biomedical and VGX Pharmaceuticals Stockholders Overwhelmingly Approve Proposed Merger DIEGO, CA and BLUE BELL, PA May 29, 2009 Inovio Biomedical Co
Read more →INO: Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 805-491-8313 Inovio Biomedical Reports First Quarter 2009 Financial Results
Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 805-491-8313 Inovio Biomedical Reports First Quarter 2009 Financial Results SAN DIEGO, CA May 14, 2009 Inovio Biomedical Corporation (NYSE AMEX: INO) ( Inovio ) today rep
Read more →INOExhitit 99.1 NEWS RELEASE Immediate Release CONTACTS : Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 805-491-8313 Inovio Biomedical s Registration Statement in
CONTACTS : Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 805-491-8313 Inovio Biomedical s Registration Statement in Connection with Proposed Merger with VGX Pharmaceuticals Declared Effective 2009 Inovio Biomedical C
Read more →INO: Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 805-491-8313 Ng Tee Khiang Appointed to Inovio Biomedical s Board o
CONTACTS : Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 805-491-8313 Ng Tee Khiang Appointed to Inovio Biomedical s Board of Directors SAN DIEGO, April 06, 2009 Inovio Biomedical Corporation (NYSE Amex: INO), a l
Read more →INO: Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 805-491-8313 Inovio Biomedical and VGX Pharmaceuticals Extend Completion Date for Definit
Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Jeff Richardson, Richardson & Associates, 805-491-8313 Inovio Biomedical and VGX Pharmaceuticals Extend Completion Date for Definitive Merger Agreement DIEGO, March 31, 2009 Inovio Biomedical Corporation (NYSE Alt
Read more →INOVGX Pharmaceuticals LOGO] VGX Pharmaceuticals Oral Anti-Inflammatory Drug Safe in Phase I Study Multiple ascending dose study finds VGX -1027 safe, well-tolerated, and orally bio-available Blue Bell, PA
Pharmaceuticals LOGO] VGX Pharmaceuticals Oral Anti-Inflammatory Drug Safe in Phase I Study Multiple ascending dose study finds VGX -1027 safe, well-tolerated, and orally bio-available Blue Bell, PA - March 26, VGX Pharmaceuticals, a biopharmaceutical company that is develo
Read more →INO: Investors: Bernie Hertel 858-410-3101 Media: Jeff Richardson 805-491-8313 Director Resigns from Inovio Biomedical s Board
Investors: Bernie Hertel 858-410-3101 Media: Jeff Richardson 805-491-8313 Director Resigns from Inovio Biomedical s Board SAN DIEGO, February 6, 2009 Inovio Biomedical Corporation (NYSE Alternext: INO), a leader in enabling the development of DNA vaccines using electroporatio
Read more →INOInvestors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Ron Trahan, Ronald Trahan Associates Inc., 508-359-4005, x108 Inovio Biomedical and VGX Pharmaceuticals Amend M
Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Ron Trahan, Ronald Trahan Associates Inc., 508-359-4005, x108 Inovio Biomedical and VGX Pharmaceuticals Amend Merger Agreement DIEGO, December 08, 2008 Inovio Biomedical Corporation (INO: NYSE Alternext, former
Read more →INOInvestors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Ron Trahan, Ronald Trahan Associates Inc., 508-359-4005, x108 Inovio Biomedical and VGX Pharmaceuticals to High
CONTACTS Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Ron Trahan, Ronald Trahan Associates Inc., 508-359-4005, x108 Inovio Biomedical and VGX Pharmaceuticals to Highlight Electroporation-Delivered DNA Vaccines at International DNA Vaccines Conference SA
Read more →INOInvestor Relations Media Relations Bernie Hertel Ronald Trahan Phone: (858) 410-3101 Phone: (508) 359-4005, x108 DNA Vaccine Company Inovio Biomedical Reports Third Quarter 2008 Financial Results
Investor Relations Media Relations Bernie Hertel Ronald Trahan Phone: (858) 410-3101 Phone: (508) 359-4005, x108 DNA Vaccine Company Inovio Biomedical Reports Third Quarter 2008 Financial Results DIEGO, CA November 7, 2008 Inovio Biomedical Corporation (AMEX: INO) ( Inovio
Read more →INOVGX Pharmaceuticals Awarded $23.5 Million NIH Contract to Develop DNA-Based Preventive HIV Vaccine Delivered Via Electroporation US government grant supports preclinical and clinical development, manufacturing and other
VGX Pharmaceuticals Awarded $23.5 Million NIH Contract to Develop DNA-Based Preventive HIV Vaccine Delivered Via Electroporation US government grant supports preclinical and clinical development, manufacturing and other activities for VGX s HIV DNA vaccine Blue Bell, PA - Oc
Read more →INOInvestors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Ron Trahan, Ronald Trahan Associates Inc., 508-359-4005, x108 Inovio Awarded US Army Contract for Bio-Defense V
Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Ron Trahan, Ronald Trahan Associates Inc., 508-359-4005, x108 Inovio Awarded US Army Contract for Bio-Defense Vaccine Research Using its Electroporation Delivery Technology SAN DIEGO, Sept 23, 2008 Inovio Biom
Read more →INOTranscript of Inovio Biomedical Corporation (INO) Investor Conference Call
Avtar Dhillon, M.D., President and Chief Executive Officer of Inovio J. Joseph Kim, Ph.D., Co-Founder, President, and CEO of VGX Pharmaceuticals Bernie Hertel, Director of Corporate Communications Thank you for standing by. Welcome to today s conference call. During this pr
Read more →INOInvestors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Ron Trahan, Ronald Trahan Associates Inc., 508-359-4005, x108 Inovio Biomedical and VGX Pharmaceuticals Sign Me
Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Ron Trahan, Ronald Trahan Associates Inc., 508-359-4005, x108 Inovio Biomedical and VGX Pharmaceuticals Sign Merger Agreement Conference call with CEOs of Inovio and VGX Tuesday, July 8 9am Eastern Time US di
Read more →INOThis Employment Agreement (the Agreement ) is made as of the 12 th day of March, 2008, AMONG: INOVIO BIOMEDICAL CORPORATION, a Delaware corporation having its principal place of business at 11494 Sorrento Valley Road, Sa
This Employment Agreement (the Agreement ) is made as of the 12th day of March, 2008, INOVIO BIOMEDICAL CORPORATION, a Delaware corporation having its principal place of business at 11494 Sorrento Valley Road, San Diego, California, U.S.A., 92121 GENETRONICS, INC., a Californ
Read more →INO: Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Ron Trahan, Ronald Trahan Associates Inc., 508-359-4005, x108 Therapeutic DNA-vaccine company Inovio Biomedic
Investors: Bernie Hertel, Inovio Biomedical, 858-410-3101 Media: Ron Trahan, Ronald Trahan Associates Inc., 508-359-4005, x108 Therapeutic DNA-vaccine company Inovio Biomedical appoints Dr. Stephen Rietiker as a Director 2008 Inovio Biomedical Corporation (AMEX:INO), a lead
Read more →INOImmediate Release CONTACTS: Investor Relations Media Relations Bernie Hertel Ronald Trahan, APR Inovio Biomedical Corp. Ronald Trahan Associates, Inc. Phone: 858-410-3101 Phone: 508-359-4005, x108 Therapeuti
Investor Relations Media Relations Bernie Hertel Ronald Trahan, APR Inovio Biomedical Corp. Ronald Trahan Associates, Inc. Phone: 858-410-3101 Phone: 508-359-4005, x108 DNA vaccine company, Inovio Biomedical, Punit Dhillon to Vice President of Finance & Operations SAN DIE
Read more →Competitive Position
How INO ranks across every disease it competes inCompetitive Position is a premium feature
See how INO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial